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Abstract 
 
Identification and Evaluation of Bacterial RNA Polymerase Inhibitors Using a Novel Plasmid-
based Transcription Assay 
 
by 
 
Nathan Thomas Scharf 
 
Chair: George A. Garcia 
Tuberculosis (TB) is a global health problem caused by Mycobacterium tuberculosis with 
8-10 million new cases each year according to the World Health Organization.  The current 
treatment includes a 6-9 month treatment with four different drugs.  Due to the long treatment 
time and lack of adherence to the treatment regimen, there is a rise in the number of multi-drug 
resistant strains of Mycobacterium tuberculosis (MDR-TB).  Rifampin, a long-time staple in TB 
treatment, is an effective drug against TB which acts by inhibiting the bacterial enzyme RNA 
polymerase (RNAP).  However, there are problems of resistance to rifampin due to mutations in 
the gene encoding for RNAP and rifampin is a very effective inducer of CYP450s.  It is of interest 
to develop potent inhibitors against bacterial RNAP that are effective against both the wild-type 
M. tuberculosis RNAP and common mutant RNAPs and do not induce CYP450s. 
Nucleic acid aptamers are very useful oligonucleotides that bind specifically to a target 
molecule based on the nucleotide sequence.  An in vitro plasmid-based RNAP transcription assay 
was developed and adapted to high-throughput screening, in which a malachite green aptamer 
xi 
 
(MGA) is used as the detection method for RNA transcription.  Compounds identified were 
evaluated for activity against a panel of 10 bacterial RNAPs (E. coli and MTB - WT and RifR RNAPs), 
and active scaffolds were further studied resulting in identification of a cyanopyrimidine scaffold 
for bacterial RNAP inhibition. 
Previous studies have shown benzoxazinorifamycins to have improved activity compared 
to rifampin in vitro against RifR RNAP enzymes. Additionally, benzoxazinorifamycins have 
decreased induction of the human pregnane X receptor (hPXR), which leads to expression of 
CYP3A4 and drug-drug interactions for patients taking rifampin concurrently with HIV 
medications.  Novel benzoxazinorifamycins were evaluated for in vitro activity against WT and 
RifR bacterial RNAPs (E. coli and MTB) using the plasmid-based transcription assay.  We 
hypothesize that identification of rifamycins that do not activate hPXR and are still active against 
M. tuberculosis RNAP and M. tuberculosis in culture will allow for the development of anti-TB 
drugs that can be taken concurrently with HIV medications, as TB-HIV coinfection is a global 
problem.
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Chapter I 
Introduction 
 Despite numerous advances over the last several decades, infectious diseases remain a 
global health problem.  Infectious diseases are the third leading cause of death globally (~10% of 
global deaths), behind cardiovascular disease and cancer.1  Tuberculosis has been the leading 
cause of death in infectious diseases since 2015, ahead of HIV/AIDS and diarrheal diseases.2  Since 
the golden age of antibiotics (approx. 1950 – 1960), a time when approximately half of antibiotics 
in use today were discovered, research into and development of antibiotics significantly 
dropped.3   This is indicated by the number of antibiotics developed in each five year period from 
1980 to 2017 (Figure I-1).4,5  However, over the past few decades, there has been a growing 
number of cases of antibiotic resistant infections.6–8  There are several factors that can contribute 
0
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Figure I-1. Number of new antibiotics approved by year from 1980 – 2017.  Figure is adapted from the 
CDC Antibiotic Resistance report.  The drugs are limited to systemic agents (topical, ophthalmic solutions, 
antibodies, etc are not included).  Data is from the FDA Center for Drug Evaluation and Research. 
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to antibiotic resistance, which include misuse of antibiotics (not completing full regimen, use in 
agriculture, inappropriate prescribing, etc.).4,8  Due to the growing issue of antibiotic resistance 
coupled with the lack of novel antibiotics entering the market, there is a greater need for 
antibiotics that can combat the issues of resistance that are appearing in the clinic.8–10 
Bacteria can develop resistance to antibiotics in a variety of ways.  Major mechanisms of 
resistance include changes in membrane permeability or antibiotic residence time (efflux), 
modification/degradation of the antibiotic, or modification of bacterial target to reduce 
affinity.11,12  It is essential to adequately understand the mechanism(s) to which bacteria become 
resistant to a particular antibiotic in order to overcome the resistance. 
Tuberculosis and Mycobacterium tuberculosis 
 Tuberculosis (TB) is an infectious disease caused by the pathogen Mycobacterium 
tuberculosis, and is one of the largest global health problems, infecting an estimated 8 – 10 
million new people each year (10.4 million new cases in 2015).  Discovery of several anti-TB drugs 
initially led to an effective cure; however, tuberculosis re-emerged during the AIDS epidemic in 
the 1980s.13  After this resurgence of TB, the World Health Organization declared TB a global 
health emergency in 1993.14  TB can exist in two forms, a latent form or an active form.  In the 
latent form of TB infection, M. tuberculosis has elicited an immunological response where the 
bacterial replication is under control and the affected person cannot infect others, does not feel 
sick, and does not have any symptoms.2,15,16  A tuberculin skin test is used to detect latent TB, 
however it frequently yields false positive results among people vaccinated with the Bacillus 
Calmette-Guérin vaccine and it does not distinguish between latent and active TB.17  In an active 
TB infection, M. tuberculosis bacteria overcome the immune system suppression and remain in 
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an actively replicating phase, manifesting in the disease tuberculosis – indicated by coughing for 
weeks, chest pain, weight loss, etc.16,18  The likelihood of activation from latent TB to the active 
form is an estimated 5 to 15%, with a higher likelihood in patients coinfected with HIV.19  In 2014, 
there were an estimated 1.5 million deaths caused by TB (0.4 million with HIV coinfection).  The 
global health implications of tuberculosis and M. tuberculosis make it an infectious disease of 
great interest and importance. 
Tuberculosis Treatment and Drug-Resistant Tuberculosis 
The current treatment regimen for tuberculosis is a 6- to 9-month time course of four different 
first-line anti-tuberculosis drugs: rifampin, isoniazid, ethambutol, and pyrazinamide (Table I-1).20–
23  The global treatment success rate for newly diagnosed TB was 83% in 2014.2  The duration of 
treatment and number of drugs required for cure of tuberculosis has been tested thoroughly.24,25   
The recommended drug regimen by the World Health Organization is two months of the four 
 Table I-1.  Drugs used for the treatment of tuberculosis  
 Drug Name 
Mode of Action 
 
 First-Line  
 Isoniazid Inhibition of mycolic acid synthesis (cell wall)  
 Rifampin Inhibition of bacterial RNA synthesis  
 
Ethambutol 
Inhibition of arabinogalactan synthesis (cell 
wall) 
 
 Pyrazinamide Disruption of membrane potential  
 Second-Line   
 Aminoglycosides Inhibition of protein synthesis  
 Linezolid Inhibition of protein synthesis  
 Ethionamide/protionamide Inhibition of mycolic acid synthesis (cell wall)  
 Delamanid Inhibition of mycolic acid synthesis (cell wall)  
 Cycloserine/Terizidone Inhibition of peptidoglycan synthesis (cell wall)  
 Fluoroquinolones Inhibition of DNA synthesis  
 4-aminosalicylic acid Inhibition of dihydrofolate reductase  
 Bedaquiline Inhibition of ATP synthesis  
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first-line anti-tuberculosis drugs, followed by four months of rifampin and isoniazid, with an 
average cost of treatment of $40 per person.2 
 Due to the emergence and prevalence of resistant strains of M. tuberculosis, additional 
therapy regimens have been designed and implemented.  Strains that are resistant to rifampin 
and isoniazid are classified as multidrug-resistant TB (MDR-TB).  The current recommended 
treatment for MDR-TB and rifampin-resistant (RifR) TB is a 9- to 12-month treatment with four 
drugs (costing approximately $1000 per person), which was reduced from an 18- to 24-month 
treatment.2   The therapies for MDR-TB include some of the second-line antibiotics (Table I-1) 
that are less effective, administered intravenous or intramuscular, and have adverse side effects 
– with a 52% global treatment success rate.26–33  It is estimated that almost 10% of MDR-TB strains 
have additional resistance to fluoroquinolones and aminoglycosides and are classified as 
extensively drug-resistant TB (XDR-TB), with an estimated treatment success rate of only 28% 
(Table I-2).2  There have been some reports of tuberculosis cases that respond to few of the first 
and second line antibiotics, and have been referred to as totally drug-resistant TB. 
 
 Only two novel drugs have been developed and approved for tuberculosis recently, 
delamanid and bedaquiline, with bedaquiline being the first anti-TB drug with a novel mechanism 
Table I-2.  Treatment for drug-sensitive and drug-resistant tuberculosis 
Drug Susceptibility 
Treatment 
Duration 
Success 
Rate 
Treatment 
Cost* 
Resistance Profile 
Drug-sensitive 6 - 9 months 83% $40  Susceptible 
Multidrug-resistant 9 - 12 months 52% $1,000  Rifamycins, isoniazid 
Extensively drug-
resistant 
18 - 24 
months 
28% >$5000 
Rifamycins, isoniazid, 
aminoglycosides, fluoroquinolones 
Totally drug-resistant N/A N/A N/A Most of 1st and 2nd line drugs 
*Treatment costs are the global cost of the drugs.  Other associated medical costs are not included 
(hospitalization, etc) 
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in four decades.34  Despite the recent development and implementation of these drugs in 2014, 
resistant isolates have already been identified in the clinic.35–37  Due to the lack of new drugs and 
the emerging issues of resistance, it is essential to investigate potential classes of molecules that 
can overcome these issues of resistance and are effective against M. tuberculosis.  
Reinvestigating previously effective drug targets is an approach that has proven to be successful 
in some cases for antibiotic drug discovery.38,39 
Rifamycins, Rifampin, and Rifamycin Resistance 
 
The rifamycins are a class of natural product antibiotics derived from the bacteria 
Amycolatopsis rifamycinica.40  Subsequent studies identified rifamycin SV (Figure I-2) and other 
derivatives of rifamycin B to have good activity against M. tuberculosis and gram-positive 
bacteria.21,41  After introduction of rifamycin SV for treatment, a semisynthetic campaign was 
undertaken to obtain a compound with better oral absorption, prolonged antibacterial levels in 
the blood, and improved activity against M. tuberculosis and gram-negative bacteria.21,42  This 
eventually led to the development and implementation of rifampin for the treatment of TB, 
reducing the TB treatment time from 18 to 9 months when used in combination therapy.43,44  
Rifampin and other rifamycins are bactericidal against M. tuberculosis and other pathogens by 
inhibiting the bacterial DNA-dependent RNA polymerase (RNAP), inhibiting initiation and 
preventing formation of nascent RNA longer than 2 to 3 nucleotides.45  
The extensive chemical modifications made on the rifamycin molecule resulted in 
identifying the following relationships between rifamycin structure and its antibacterial activity.21  
• Changes in the ansa chain (C-15 to C-29) generally yields less active rifamycins 
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• Substitution or elimination of hydroxyl groups at C-21 and C-23 results in large 
decreases in activity 
• Hydroxy group at C-8 is essential for antimicrobial activity  
• Both quinone and hydroquinone systems are active for the naphthalene core 
(keto and hydroxy groups at C-1/C-4 had similar activity)  
• Compounds with a free carboxyl group are less active due to poor penetration 
• Substitutions at C-3 and C-4 are well tolerated 
  
 
 
 
Figure I-2. Structures of rifamycins of particular interest.  Numbering referenced in text 
is shown on rifamycin SV. 
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 Despite the extensive studies to identify a rifamycin analog with favorable qualities, 
culminating in the identification and commercialization of rifampin, it has been shown that 
additional progress can still be made.  Compounds have been identified with improved 
pharmacokinetic properties as well as partial amelioration of drug – drug interactions, which is 
important for the significant subpopulation of HIV patients that are coinfected with M. 
tuberculosis.46  Rifampin induces CYP3A4 via activation of the human pregnane X receptor (hPXR), 
which causes rifampin to exhibit drug – drug interactions with many other drugs.47  The rifamycin 
analog rifalazil (Figure I-2) was of particular interest because it was shown to be more potent 
against M. tuberculosis than rifampin and other analogs, and it lacked toxicity in early rodent 
studies.48  Further evaluation of rifalazil showed that it did not exhibit complete cross-resistance 
to rifampin and it was shown to not induce CYP3A4.49–51  Rifalazil was tested in phase I and phase 
II clinical trials, however it was proven to be too toxic for use against TB in humans.52 
 Rifamycin resistance in the RNA polymerase occurs at a high rate (~10-8), with an 81-bp 
core region of the rpoB gene, known as the rifampin resistance determining region (RRDR), 
accounting for ~96% of all RifR strains of M. tuberculosis.45,53–55  Mutations at three residues 
within the RRDR (S450, H445, D435) account for approximately 84% of RifR strains, and the most 
 
Table I-3.  In vitro IC50 values (µM) of rifamycins and benzoxazinorifamycins 
against M. tuberculosis WT and RifR RNA polymerase 
 
 Compound WT D435V H445Y S450L  
 Rifampin 0.017 465 610 109  
 Rifalazil < 0.01 541 172 117  
 bxRif2b < 0.01 20 171 16  
 bxRif2c < 0.01 9 437 18  
 bxRif2d < 0.01 13 574 122  
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clinically prevalent RifR mutation (S450L) accounts for ~45% of RifR MTB.54,55  Rifalazil and other 
benzoxazinorifamycins (Figure I-2) have been studied more recently for in vitro activity against 
WT and RifR bacterial RNAP, with improved activity against the most clinically relevant RifR 
mutations compared to rifampin (Table I-3).56,57  Due to the current issues of drug – drug 
interactions and RifR M. tuberculosis, it is of interest to identify novel bacterial RNAP inhibitors 
that are effective against both wild-type and RifR bacterial RNAP, do not activate hPXR, and have 
favorable toxicity profiles for the treatment of tuberculosis. 
Known Bacterial RNA Polymerase Inhibitors 
 Rifamycins is one of several classes of compounds that are known to inhibit bacterial 
RNAP.  Bacterial RNAP is a multi-subunit enzyme (Core enzyme: αββ’ω) with an associated sigma 
(σ) factor.  RNA transcription is a process that involves multiple steps for RNA to be synthesized 
within the cell.  The sigma factor allows for the RNAP to recognize and bind the -10 and -35 
consensus elements of the promoter sequence.58  The transcription cycle is made up of four 
steps: 1) assembly of the RNAP holoenzyme from core enzyme and sigma factor, 2) formation of 
promoter complex and initiation of de novo RNA synthesis, 3) elongation of RNA, and 4) 
termination of synthesis and dissociation of RNA.  Rifampin is known to inhibit the initiation of 
RNA synthesis; however, there are other compounds known to inhibit RNA polymerase via other 
mechanisms.  Some of these compounds have been identified from natural product extracts, 
where others have been identified through high-throughput screening (Table I-4).56,59–67  
Including the rifamycins, the most potent compounds are natural products or natural product 
derivatives (GE23077, Salinamide, Sorangicin).  GE23077 is the most potent inhibitor other than 
the rifamycins, but it is not permeable to most bacteria.63   
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Sorangicin is cross-resistant with the rifamycins and salinamide has the potential for off-
target effects, so these compounds are not ideal for developing an anti-TB drug.62,68  Some of the 
other RNAP inhibitors have been identified from high-throughput screens using several different 
assays such as a fluorescence-based assay using a non-native fluorescent nucleotide, measuring 
the RNAP – σ interaction (SB2), and using a radiolabeled nucleotide (CBR703).60,69,70  The 
development of a fluorescence-based transcription assay using a plasmid DNA template would 
better recapitulate how transcription occurs within the cells, compared to the assays previously 
used. 
Malachite Green Aptamer 
 RNA aptamers allow for highly specific recognition of a molecule based on the unique 
three-dimensional structure of the RNA oligonucleotide.  The malachite green aptamer is a 38 
nucleotide RNA aptamer that binds specifically to malachite green and other triphenylmethane 
dyes, yielding an increase in the dye fluorescence by restricting vibrational deexcitation.71  The 
malachite green aptamer has previously been used to detect activity of the E. coli RNAP core 
Table I-4.  Bacterial RNA polymerase inhibitors and their mechanism of action 
Compound In vitro E. coli 
RNAP IC50 (nM) 
Type of Inhibition 
SB2 series 1000 Holoenzyme assembly 
Myxopyronin 1000 Complex formation 
Lipiarmycin 3000-10000 Complex formation 
Rifampin < 10 Initiation 
GE23077 40 Initiation 
Salinamide 200 - 500 Initiation 
Sorangicin 100 Initiation 
Streptolydigin  18000 (Ki) Initiaton and elongation 
Microcin J25 1400 Initiation and elongation 
CBR703 10000 Initiation and elongation 
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enzyme using a transcription assay known as rolling circle transcription.72   Rolling circle 
transcription utilizes a circular single-stranded DNA template that binds RNAP core enzyme, and 
does not require an associated sigma factor.  The RNAP forms multiple repeats of RNA encoded 
by the DNA template, forming long RNAs via constitutive elongation.73 
Research Objectives 
 There is a need for novel anti-TB drugs that are effective against antibiotic resistant 
strains.  Reinvestigation of targets for previous drugs is an attractive approach to overcome the 
issues of site-specific resistance.  When first introduced, rifampin was a major breakthrough in 
the treatment for TB; however, issues of resistance have made it important for new anti-TB drugs 
to enter the pipeline.   
 The focus of this dissertation is to identify and evaluate compounds for inhibition of 
bacterial RNAP.  Although several assays have been developed to identify and evaluate inhibitors 
of bacterial RNAP, the development of a novel plasmid-based transcription assay utilizing the 
malachite green aptamer is of interest because it would be cost-effective, a better representation 
of cellular transcription, and amenable to high-throughput screening.  This transcription assay 
can also be used to evaluate novel bacterial RNAP inhibitors for their activity against E. coli and 
MTB RNAP.  The questions answered in this dissertation are listed below. 
• Chapter II: Can a plasmid-based transcription assay be developed for use in a high-
throughput screening assay? 
• Chapter III: Can novel bacterial RNA polymerase inhibitors be identified from a high-
throughput screen? 
11 
 
• Chapter IV:  Are any of the scaffolds identified from the high-throughput screen specific 
inhibitors of bacterial (E. coli and MTB) RNA polymerase that could be further developed 
as a potent inhibitor?  
• Chapter V: Are any of our novel benzoxazinorifamycins more potent against bacterial 
RNAP (E. coli and MTB) and M. tuberculosis in culture than previously developed 
compounds? 
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Chapter II 
Development and Optimization of In vitro Plasmid-Based Transcription Assay Utilizing 
Malachite Green Aptamer Detection 
 Bacterial RNA polymerase (RNAP) is the target of the first line anti-tuberculosis drug 
rifampin.  Issues of site-specific resistance to rifampin have made it important to identify novel 
anti-TB drugs that are effective against resistant strains of M. tuberculosis (MTB) for the 
treatment of multidrug-resistant and extensively drug-resistant TB. 
Several transcription assays have been utilized to assess RNAP activity in vitro; however, 
none of them are optimally suitable for high-throughput screening and follow-up.  It is of interest 
to develop an assay that is efficient, sensitive, low cost of materials, and more accurately reflects 
the cellular transcription process.  A novel plasmid-based transcription assay utilizing a 
fluorescence reporter to detect the product RNA should achieve those goals.  Unlike rolling circle 
transcription, the plasmid-based transcription assay requires a sigma factor for recognition and 
binding to the DNA promoter sequence.  Additionally, a plasmid-based assay utilizes a double-
stranded DNA template, so unwinding of the DNA and open complex formation is required in 
order for initiation and elongation to occur.74  A fluorescence assay is preferred over an assay 
utilizing a radiolabeled nucleotide because of the hazards and costs associated with radioactive 
materials, which would not be amenable to a high-throughput screen (HTS).  A malachite green 
aptamer (MGA) assay was chosen over an assay that utilizes a non-native NTP analog that 
13 
 
releases a fluorescent molecule when incorporated into the RNA because using a native substrate 
is preferred and there are substantial costs associated with preparation of the nucleotide analog. 
Therefore, with the goal of developing an assay that was amenable to an HTS, we 
incorporated the malachite green aptamer gene into a small, high-copy plasmid (pTZ18U).  After 
a series of optimization steps, we developed a plasmid containing multiple repeats of the MGA 
and developed assay conditions that gave a robust signal when incubated with E. coli RNAP. 
Materials and Methods 
Materials 
All reagents were purchased from Sigma-Aldrich (St Louis, MO), unless otherwise 
specified.  Nucleoside triphosphates were purchased from Chem-Impex International (Wood 
Dale, IL).  QIAprep Spin Miniprep Kit, QIAquick Gel Extraction Kit, QIAquick Nucleotide Removal 
Kit, and Ni-NTA agarose were from Qiagen (Valencia, CA).  Yeast extract, bactotryptone, 
kanamycin, DTT, Corning microplates, Amicon Centrifugal Filter Units were purchased from 
Fisher Scientific (Hampton, NH).  Carbenicillin and isopropyl β-D-1-thiogalactopyranoside (IPTG) 
were purchased from Gold Biotechnology (St Louis, MO).  Chloramphenicol was purchased from 
Tokyo Chemical Industry (Tokyo, Japan).  Taq DNA polymerase, T4 DNA ligase, Antarctic 
Phosphatase, deoxynucleoside triphosphates (dNTPs), and all restriction enzymes were 
purchased from New England Biolabs (Ipswich, MA).  PfuUltra high-fidelity DNA polymerase was 
purchased from Agilent Technologies (Santa Clara, CA).  pCR2.1-TOPO Cloning Kit, Quant-iT™ 
RiboGreen® RNA reagent and all synthetic oligonucleotides were purchased from Invitrogen 
(Carlsbad, CA), unless otherwise specified.  Oligonucleotide primers used in this study are listed 
in Table II-1.  Oligonucleotides for nanocircle preparation (Table II-2) were purchased from 
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Integrated DNA Technologies (Coralville, IA).  Plasmids used and prepared in this study are listed 
in Table II-3.  The Bio-Rad Protein Assay Kit was purchased from Bio-Rad (Hercules, CA).  DNA 
sequencing was performed by the University of Michigan Biomedical Resources Core Facility.  
MALDI-TOF mass spectrometry was performed by the University of Michigan Chemistry Mass 
Spectrometry Core.  GELaseTM Agarose Gel-Digesting Preparation was purchased from Epicentre 
(Madison, WI).  Seaplaque® Agarose was from Lonza (Rockland, ME). 
Table II-1.  List of oligonucleotides used  
Oligonucleotide Name                 
(Restriction enzyme, if any) Sequence, 5' - 3' (Restriction site underlined, if any) Length 
prrn-Fwd (EcoRI) GAATTCTCGTGGAGAACCTG 20 
prrn-Rev (XhoI) CTCGAGTGCCAGTCTAATACA 21 
4xMGA-Fwd (XhoI) CTCGAGCGGCAGCACGTCGAC 21 
4xMGA-Rev (HindIII) AAGCTTGCATGCCTGCAGGTCC 22 
lacUV5-Fwd TTATGCTTCCGGCTCGTATAATGTGTGGAATTGTGAGCG 39 
lacUV5-Rev CGCTCACAATTCCACACATTATACGAGCCGGAAGCATAA 39 
lacCONS-Fwd ATTAGGCACCCCAGGCTTGACACTTATGCTTCCGGCTCGT  40 
lacCONS-Rev ACGAGCCGGAAGCATAAGTGTCAAGCCTGGGGTGCCTAAT 40 
280Del-Fwd CGCGGCCTTTTTACGGTTCCGGCACCCCAGGCTTTACAC 39 
280Del-Rev GTGTAAAGCCTGGGGTGCCGGAACCGTAAAAAGGCCGCG 39 
358Del-Fwd (XbaI) CCCCGTCAAGCTCTAGAATCGGGGGCTCC 29 
358Del-Rev (XbaI) GGAGCCCCCGATTCTAGAGCTTGACGGGG 29 
MGAclone-Fwd (NheI) GCTAGCGGCAGCACGTCGAC 20 
MGAclone-Rev (XbaI) GGACCGAAGTCCGCTCTAGAGG 22 
 
The plasmid construct pVS10 for WT E. coli RNAP expression was a generous gift from Dr. 
Irina Artsimovitch (Ohio State University).  The preparations of pVS10 E. coli RNAP expression 
plasmids for β subunit mutations D516V, H526Y, S531L were previously described.56  The pU6+19 
vector containing the four MGA repeats (pU6+19-4xMGA) was a generous gift from Dr. Marit 
Nilsen-Hamilton (Iowa State University).75  The pFPV27-prrn plasmid was a generous gift from Dr. 
Jaya Tyagi (India Institute of Medical Sciences).76 
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Expression and Purification of E. coli WT RNAP 
 E. coli WT RNAP was expressed and purified from the plasmid construct pVS10.  The pVS10 
plasmid encoding the four subunits for RNAP core enzyme (α, β, β’, ω) was transformed into E. 
coli BL21(DE3) and grown in 1 L 2xTY with carbenicillin at 30°C until OD600 = 1.0 -1.2, at which 
point protein expression was induced with 1 mM IPTG.  The cells were grown for an additional 4 
hrs at 30°C, then harvested by centrifugation.  The cell pellet was suspended in RNAP lysis buffer 
(50 mM Tris-HCl, 1 mM EDTA, 10 mM β-mercaptoethanol [β-ME], pH = 8.0 at 4°C) and 
supplemented with 2 mM PMSF.  Cells were lysed by sonication, and the lysate was cleared by 
centrifugation (35,000 x g, 30 min, 4°C).  Protein was precipitated by addition of 10% polymine P 
(pH = 7) to a final concentration of 0.5% polymine P, incubated at 4°C for 15 min with shaking, 
followed by centrifugation (6,000 x g, 20 min, 4°C).  The precipitate was resuspended to 
homogeneity with a glass rod in 15 mL of TGEB buffer (10 mM Tris-HCl, 5% glycerol, 0.1 mM 
EDTA, 5 mM β-ME, pH = 8.0 at 4°C) containing 0.4 M NaCl and collected by centrifugation (6,000 
x g, 20 min, 4°C), followed by resuspension of RNAP in 15 mL of TGEB containing 1 M NaCl to 
solubilize RNAP.  The RNAP was then clarified by centrifugation (8,000 x g, 20 min, 4°C), and the 
resulting protein in the supernatant was precipitated by addition of an equal volume of saturated 
ammonium sulfate solution to the supernatant and incubated at 4°C with constant, gentle 
shaking for 1 hr.  After centrifugation (10,000 x g, 20 min 4°C), the protein pellet was dissolved in 
TGEB containing 50 mM NaCl and dialyzed against 2 L of the same buffer overnight at 4°C.  The 
dialyzed RNAP was incubated with 2 mL of Ni-NTA agarose with constant shaking at 4°C for 1 hr.  
The mixture was then applied to a gravity-flow column and washed with TGEB containing 50 mM 
NaCl and imidazole as follows:  5 CVs – 5 mM imidazole, 5 CVs – 10 mM imidazole, 5 CVs – 20 
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mM imidazole, 5 CVs – 40 mM imidazole, 5 CVs – 100 mM imidazole.  Fractions containing RNAP 
core as identified by SDS-PAGE and Coomassie staining were pooled and concentrated using a 10 
kDa MWCO Amicon Ultra-15 Centrifugal Filter Unit.  Concentrated protein was applied to a 
HiPrep 16/60 Sephacryl S-300 HR column (GE Healthcare) equilibrated with TGED containing 200 
mM NaCl.  Eluted RNAP was concentrated using a 10 kDa Amicon Ultra-15 Centrifugal Filter Unit 
and flash-frozen in nitrogen before storing at -80°C. 
Expression and Purification of E. coli σ70 
E. coli BL21(DE3) containing pET15b-Sig70 (WT rpoD) were grown in 1 L 2xTY at 30°C until 
OD600 ~ 1.0 – 1.2, then induced with 1 mM IPTG and allowed to grow for an additional 4 hrs at 
30°C.  Cells were harvested by centrifugation and resuspended in 15 mL σ70 lysis buffer (20 mM 
Tris-HCl, 0.4 M NaCl, 1 mM EDTA, 2 mM PMSF, 5 mM β-ME, 5% glycerol, pH = 8.0 at 4°C) then 
passed through a French press three times (20,000 psi) on ice.  The lysate was cleared by 
centrifugation (35,000 x g, 30 min, 4°C) and the supernatant was applied to a 2-mL Ni2+ column 
equilibrated with σ70 lysis buffer, then washed with 8 CVs of the same buffer.  The column was 
then washed with 9 CV of σ70 wash buffer (σ70 lysis buffer + 15 mM imidazole and 50 mM NaCl), 
followed by elution with 6 CV of σ70 elution buffer (10 mM Tris-HCl, pH 8.0 at 4°C, 50 mM NaCl, 
5% glycerol, 5 mM β-ME, 200 mM imidazole).  Next, the protein was applied to a 5-mL Q 
Sepharose column equilibrated with σ70 elution buffer (without imidazole), and a linear gradient 
of 0.05 – 1 M NaCl over 40 CVs.  Fractions containing σ70 were determined by SDS-PAGE, 
combined, and flash-frozen in liquid N2. 
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 Preparation of DNA Nanocircle 
A ssDNA nanocircle (MG-45) encoding the malachite green aptamer and linker sequence 
5’–TAAAAAC–3’ was prepared similarly to those previously described, circularizing a 5’-
phosphorylated linear oligonucleotide with T4 DNA ligase using a complementary splint DNA 
(Table II-2).72  In short, 5’-phosphorylated linear template (10 µM) and splint DNA (15 µM) were 
combined in 1x T4 DNA ligase buffer, denatured at 75°C for 10 min, then either allowed to slowly 
reach room temperature or placed on ice to quickly cool the reaction.  BSA and T4 DNA ligase 
were added to final concentrations of 100 µg/mL and 4000 U/mL, and ligated overnight at 16°C.  
Exonuclease I was added to a final concentration of 200 U/mL and incubated at 37°C for 45 min, 
followed by heat inactivation.  The reaction was ethanol precipitated, resuspended in water, 
further purified via QIAquick Nucleotide Removal Kit, and quantified on a Synergy H1 Hybrid plate 
reader using a Take3 plate.  Purity was verified on a 16% polyacrylamide gel and visualized by 
staining with ethidium bromide.  The weight of the nanocircle was determined by MALDI-TOF 
mass spectrometry.  A 104 nt ssDNA nanocircle (MG-52) using the same sequence as Furukawa 
et al. was also prepared as described above, using the appropriate oligonucleotides (Table II-2).72  
The ssDNA templates were analyzed by MALDI-TOF to verify their size. 
Table II-2.  Sequences of oligonucleotides for nanocircle preparation  
Oligonucleotide 
Name Sequence, 5' - 3' 
Lengt
h 
Linear DNA (MG-45) pGTTACCTGGCTCTCGCCAGTCGGGATCCGTTTTTAGGATCCATTC 45 
Splint DNA (MG-45) CCAGGTAACGAATGGATCC 19 
Linear DNA (MG-52) 
pGGCCACAGGATCCATTCGTTACCTGGCTCTCGCCAGTCGGGATCCACGT
ACC 
52 
Splint DNA (MG-52) CCTGTGGCCGGTACGTGG 18 
*Underlined section in green represents DNA encoding for MG aptamer 
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Cloning, Preparation of MGA Plasmid Constructs 
 The prrn operon (prrn Op) was amplified by PCR from pFPV27-prrn with oligonucleotides 
prrn-Fwd and prrn-Rev, and the DNA encoding four MGA repeats was amplified by PCR from 
pU6+19-4xMGA (contains a 5’-TAAAAAC-3’ linker between repeats) with oligonucleotides 
4xMGA-Fwd and 4xMGA-Rev.  Each PCR product was subcloned using the TOPO TA Cloning Kit 
(pEXP-5-NT/TOPO).  The resulting plasmids, TOPO-prrn and TOPO-4xMGA, were isolated via 
miniprep (Qiagen) and confirmed by DNA sequencing.  The prrn and 4xMGA DNA fragments were 
inserted into pTZ18U by first digesting TOPO-prrn (EcoRI and XhoI), TOPO-4xMGA (XhoI and 
HindIII), and pTZ18U (EcoRI and HindIII).  The prrn and 4xMGA fragments, and pTZ18U vector, 
were gel purified from Seaplaque® agarose gel with GELaseTM according to the vendor’s protocol.  
The three purified samples were ligated with T4 DNA ligase and then transformed into TOP10 
chemically competent E. coli.  The resulting plasmid, pTZ18U-4xMGA, was isolated via miniprep 
and confirmed with DNA sequencing (Figure II-1). 
The lac wild-type (lacWT) promoter on pTZ18U-4xMGA was mutated to lacUV5 via two-
stage site-directed mutagenesis77 with the complementary oligonucleotides lacUV5-Fwd and 
Figure II-1. Overview of modifications to prepare pMGA12 plasmid template.  Original plasmid template 
pTZ18U-4xMGA (left) was modified by addition of eight MG repeats, mutation of promoter to lacUV5, 
removal of portion of F1 ori and DNA upstream of promoters. 
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lacUV5-Rev with PfuUltra DNA polymerase, followed by DpnI digestion, and transformation into 
TOP10 E. coli.  The resulting plasmid, pTZ18U-4xMGA-lacUV5, was isolated via miniprep and 
confirmed with DNA sequencing.  The lacUV5 promoter on pTZ18U-4xMGA-lacUV5 was mutated 
to lacCONS using the same mutagenesis procedure with complementary oligonucleotides 
lacCONS-Fwd and lacCONS-Rev to give the plasmid pTZ18U-4xMGA-lacCONS. 
A 280 bp region upstream of the lacWT promoter on pTZ18U-4xMGA was removed via 
mutagenesis using complementary oligonucleotides (280Del-Fwd and 280Del-Rev), resulting in 
the plasmid pTZ18U-4xMGA-280bpDel. 
Additional MGA repeats were incorporated into the pTZ18U vector using an iterative 
cloning technique with the compatible restriction overhangs of NheI and XbaI (Figure II-2).  The 
4xMGA fragment was amplified by PCR from pTZ18U-4xMGA using oligonucleotides MGAclone-
Fwd and MGAclone-Rev.  The PCR fragment was subsequently subcloned using the TOPO Cloning 
Kit (pCR2.1-TOPO).  The resulting plasmid, TOPO-4xMGA-NheI, was isolated and confirmed by 
DNA sequencing.  pTZ18U-4xMGA was digested with XbaI, dephosphorylated with Antarctic 
Figure II-2. Iterative cloning technique to insert additional MGA repeats.  Digestion of TOPO-4xMGA-NheI 
template with NheI and XbaI results in 4xMGA insert with compatible restriction overhangs (top).  
Insertion of 4xMGA insert to plasmid template results in addition of MGA repeats and regeneration of 
XbaI restriction site. 
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Phosphatase, and then purified by gel extraction. TOPO-4xMGA-NheI was restricted with NheI 
and XbaI, and the 4xMGA fragment was purified by gel extraction.  The 4xMGA fragment was 
ligated with the linearized pTZ18U-4xMGA with T4 DNA ligase, resulting in pTZ18U-8xMGA.  This  
process was repeated to prepare a plasmid with 12 MGA repeats, pTZ18U-12xMGA. 
The lacWT promoter on pTZ18U-12xMGA was mutated to lacUV5 and the 280-bp region 
upstream of the promoters was deleted in the same manner as described above to give 
pMGA12+F1ori.  A 358-bp region from the F1 ori was then removed from pMGA12+F1ori.  First, 
an XbaI restriction site was inserted by mutagenesis using the complimentary oligonucleotides 
358Del-Fwd and 358Del-Rev.  The resulting plasmid was digested with XbaI and vector fragment 
was gel purified from an agarose gel using the QIAquick Gel Extraction Kit.  The vector was ligated 
with T4 DNA ligase and then transformed into TOP10 E. coli.  The resulting plasmid, pMGA12, 
Table II-3.  List of plasmids used  
Plasmid Name Description Reference 
pFPV27-prrn pFPV27 vector containing MTB prrn operon (76) 
pU6+19-4xMGA plasmid containing four repeats of MGA (75) 
TOPO-prrn pEXP5-NT vector containing prrn operon This study 
TOPO-4xMGA pEXP5-NT vector containing four MGA repeats This study 
pTZ18U-4xMGA 
pTZ18U vector containing prrn operon and four MGA 
repeats 
This study 
pTZ18U-4xMGA-lacUV5 pTZ18U-4xMGA with lacUV5 promoter This study 
pTZ18U-4xMGA-lacCONS pTZ18U-4xMGA with lacCONS promoter This study 
pTZ18U-4xMGA-
280bpDel 
pTZ18U-4xMGA with 280 bp deletion upsteam of lacWT This study 
TOPO-4xMGA-NheI 
pCR2.1-TOPO vector containing four MGA repeats with 
NheI restriction site upstream 
This study 
pTZ18U-8xMGA pTZ18U-4xMGA with four additional MGA repeats (8 total) This study 
pTZ18U-12xMGA pTZ18U-8xMGA with four additional MGA repeats (12 total) This study 
pMGA12+F1ori pTZ18U-12xMGA with lacUV5 and 280bp deletion This study 
pMGA12 pMGA12+F1ori with 358 bp deletion downstream of MGA This study 
pVS10 Expression vector for E. coli RNAP core enzyme (60) 
pET15b-Sig70 Expression vector for E. coli σ70 
K. Murakami 
(unpublished) 
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was isolated and confirmed by DNA sequencing (Figure II-1).  Only a portion of the F1 ori was 
removed because attempts to remove the entire F1 ori were unsuccessful. 
Rolling Circle Transcription Assay 
The activity of E. coli RNAP was measured via rolling circle transcription in a similar fashion 
to that previously described.56  Transcription reactions (25 μL) were incubated at 37°C for 2 hours 
upon initiation by addition of NTPs under the following conditions: 40 mM Tris-HCl (pH 8.0), 50 
mM KCl, 10 mM MgCl2, 0.01% Triton X-100, 8 mM DTT, 1.12 U/μL RNase inhibitor, 160 nM ssDNA 
nanocircle template, 80 nM core E. coli RNAP, and 500 μM each NTP. 
Plasmid-Based in vitro Transcription Assay 
The activity of E. coli RNAP was measured via plasmid-based, in vitro transcription using 
the plasmid templates prepared.  Transcription reactions were prepared the same way as for 
rolling circle transcription with the following modifications: 80 nM plasmid template and 80 
nM/240 nM E. coli RNAP/σ70 was used, unless otherwise specified in the results. 
RiboGreen Detection of Transcription 
Transcription reactions prepared as described above were monitored by measuring the 
fluorescence of RiboGreen as follows.  After 2 hr incubation at 37°C, 2 µL of the reactions were 
quenched on ice with 73 µL of 10 mM Tris/1 mM EDTA (pH = 7.5).  Then, 75 µL of 1:200 RiboGreen 
in water was added to each well, measuring fluorescence (Ex/Em = 480nm/520nm) after 5 min 
incubation. 
Malachite Green Detection of Transcription 
 Transcription reactions prepared as described above were monitored by measuring the 
fluorescence of malachite green as follows.  After 2 hr incubation at 37°C, the reaction was halted 
22 
 
by incubating on ice and adding 75 µL of cold 40 µM malachite green in water.  After 5 min on 
ice, malachite green fluorescence was detected at excitation and emission wavelengths of 628 
nm and 660 nm, respectively. 
Inhibition of E. coli WT RNAP by Rifampin 
The rifampin IC50 value on E. coli WT RNAP was determined using the plasmid-based 
transcription assay.  Reactions of 50 µL for E. coli WT RNAP were prepared in a 96-well plate 
(Corning 96-Well Half Area Black Flat Bottom Polystyrene NBSTM microplate) as follows.  In each 
well, 24 µL of a 2x E. coli reaction buffer solution [80 mM Tris-HCl (pH = 7.5 at 23°C), 100 mM KCl, 
20 mM MgCl2, 0.02% Triton X-100, 16 mM DTT, 5 nM pMGA12, 1 mM NTPs] was added, 2 µL of 
DMSO or varying concentrations of two-fold serially diluted rifampin in DMSO (final, 2.5 – 80 
nM), followed by 24 µL of a 2x RNAP solution (10 nM RNAP, 30 nM σ70).  Reactions were incubated 
at 37°C for 2 hrs, followed by addition of 50 µL of 150 µM MG in water, and incubation on ice for 
10 min. Fluorescence was measured at excitation and emission wavelengths of 628 and 660 nm, 
respectively.  Data were normalized to percent activity (DMSO = 100% activity, no RNAP = 0% 
activity), then fit by nonlinear regression to Eq. (1) where M0 = log of compound concentration, 
M1 = log of IC50, M2 = hill slope, M3 = lower limit of the curve, and M4 = upper limit of the curve. 
(1)  𝑦 = 𝑀3 +
(𝑀4−𝑀3)
(1+10(𝑀0−𝑀1)×𝑀2)
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Results 
Preparation of ssDNA Nanocircle 
 To evaluate the difference between RiboGreen and malachite green detection, single-
stranded DNA nanocircles were prepared with either a 52 or 45 nucleotide (nt) sequence to 
recapitulate what has been done previously72 or to be analogous to the plasmid template, 
respectively.  Two different sized nanocircles were prepared by modifying the preparation 
procedure, with a larger nanocircle forming (Figure II-3, Lane 6) when allowed to cool slowly 
during oligonucleotide annealing. 
 The molecular weights of the nanocircles were determined by MALDI-TOF.  It was 
determined that the larger nanocircle prepared contained two repeats of the 45-nt sequence, 
making it 90-nt in length with a molecular weight of ~27.8 kDa (Figure II-4).  The peak at 17.6 kDa 
is potentially explained by residual splint DNA if three pieces of splint DNA annealed together at 
the ends (MW = 5821 x 3 = 17463 Da) The 90-nt nanocircles were more active than the 45-nt 
nanocircles and were therefore used for the transcription assays.  The nanocircles MG-45 and 
1     2      3      4     5     6 kb 
1 
0.5 
0.1 
Figure II-3. 16% PAGE of synthesized DNA nanocircles.  Lane 1: 100 bp ladder, Lane 2: linear DNA (MG-
45), Lane 3: splint DNA (MG-45), Lane 4: hybridized linear and splint DNA (MG-52), Lane 5: quick cool 
reaction, Lane 6: slow cool reaction 
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MG-52 refer to the larger (90- and 104-nt) nanocircles. The MG-45 nanocircle was used instead 
of the MG-52 nanocircle because it has the same sequence as in the plasmid template, and the 
transcription signal for each nanocircle were similar to one another (data not shown). 
RiboGreen vs Malachite Green Detection 
 The activity of E. coli WT RNAP was assessed in rolling circle transcription using MG-45 
and in the plasmid-based transcription assay utilizing pTZ18U-4xMGA as the plasmid template.  
After the transcription reactions and fluorescence measurements (RiboGreen and malachite 
green) of both the rolling circle transcription assay and the plasmid-based transcription assay, it 
was determined that the total fluorescence signal from the MGA detection was lower (Figure II-
Figure II-4. Mass spectra of circularized MG-45.  Mass spectra was obtained by MALDI-TOF on a Bruker 
Autoflex Speed mass spectrometer in positive ion linear mode, calibrated with a mixture of proteins in 
sinapinic acid.  Sample was rinsed with 0.1 M triethylammonium acetate. 
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5).  However, the signal to noise (S/N) ratio for MGA compared to RiboGreen was significantly 
better (Table II-4).  The plasmid-based assay had S/N of 1.6:1 and 11:1 for RiboGreen and 
malachite green, respectively.  The rolling circle transcription assay had S/N of 6:1 and 460:1 for 
RiboGreen and malachite green, respectively.  Despite the improved signal to noise for the MGA 
assays, the fluorescence signal was significantly lower.  The MGA assays required the sensitivity  
on the Synergy H1 Hybrid plate reader to be higher. 
Table II-4.  Average fluorescence values of RiboGreen and MGA detection (RCT 
vs Plasmid-based transcription) 
 RiboGreen MGA 
NTP RCT Plasmid RCT Plasmid 
 - 2400 42500 30 540 
 + 14400 67900 13700 5900 
Signal to 
Noise 
6.0 1.6 460 11 
 
 
Figure II-5.  Fluorescence detection of rolling circle transcription and plasmid-based transcription.  
Fluorescence is measured using RiboGreen (RG) or the malachite green aptamer (MGA).  Fluorescence is 
at different instrument sensitivity values (RiboGreen = 100, MGA = 150). 
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Modifications to Plasmid Template 
 Several modifications were made to the initial plasmid construct, pTZ18U-4xMGA, with 
the goal to increase the overall signal of the assay, and decrease the amount of plasmid required 
for a high-throughput screen.  Each of the modifications made were done with at least one of 
these goals in mind.  The size of the plasmid was decreased by the initial 280-bp deletion 
upstream of the promoter sequences and by the 358-bp deletion downstream of the MGA 
repeats.  The lacWT promoter was mutated to the lac consensus promoter (lacCONS) as well as 
the lacUV5 promoter, which has been shown to be a strong promoter within the cell.78  Additional 
sets of four repeats were successfully cloned into the plasmid pTZ18U-4xMGA using an iterative 
cloning technique with the compatible restriction sites NheI and XbaI.  The use of these two 
restriction sites allowed for the regeneration of an XbaI restriction site downstream of the 
inserted 4xMGA fragment (Figure II-2).  Addition of repeats beyond 12 MGA repeats was 
unsuccessful.  Transformations of plasmids containing numerous repeats (i.e., 12 or more) often 
led to the loss or removal of some repeats during the transformation and cellular replication 
process.  The lacUV5 and 280-bp deletion were successfully mutated onto the plasmid with 12 
MGA repeats (pTZ18U-12xMGA) to give pMGA12+F1ori.  After deletion of a 358-bp portion of 
the F1 ori downstream of the MGA repeats, the plasmid pMGA12 was prepared.  pMGA12 
contains the following modifications from the original plasmid:  it has 8 additional MGA repeats 
(12 total), contains the lacUV5 promoter sequence, and is 8% smaller (252 bp) than pTZ18U-
4xMGA (Figure II-1). 
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Effect of Plasmid Modifications on E. coli RNAP Transcription 
 The effects of the DNA deletions, promoter type, and number of MGA repeats were 
determined using E. coli WT RNAP in the plasmid-based in vitro transcription assay with malachite 
green detection.  The results are shown in Figure II-6; comparing the effect of different promoters 
and a deletion upstream of the promoters (top left), addition of multiple sets of MGA repeats 
(top right), and deletion of DNA downstream of the MGA repeats (bottom).  The lacUV5 promoter 
was shown to be approximately 1.6-fold more active in vitro than lacWT, while the consensus 
sequence (lacCONS) had similar activity to lacWT (Figure II-6, top left and Table II-5).  The plasmid 
containing a 280-bp deletion upstream of the lacWT promoter (pTZ18U-4xMGA-280bpDel) was 
slightly more active than pTZ18U-4xMGA (3-fold, Table II-5), and was approximately 10% smaller 
Figure II-6. Plasmid-based transcription assay using different plasmid DNA templates.  Top left: Effect of 
lac promoter and 280 bp deletion upstream of promoter on E. coli WT RNAP transcription activity.  Top 
right: Effect of additional MGA repeats on E. coli WT RNAP transcription activity.  Bottom:  Effect of F1 ori 
deletion (358 bp) downstream of MGA repeats on E. coli WT RNAP transcription activity. 
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in size.  The addition of more MGA repeats onto the plasmid template via the iterative cloning 
technique resulted in a linear increase in the fluorescence signal from the transcription assay, 
using E. coli WT RNAP (Figure II-6, top right).  The plasmid templates with 8 and 12 total MGA 
repeats (pTZ18U-8xMGA and pTZ18U-12xMGA), resulted in approximately a 1.8- and 2.8-fold 
increase relative to pTZ18U-4xMGA, respectively (Table II-5).  The pMGA12+F1ori and pMGA12 
plasmid templates were used for transcription by E. coli WT RNAP, using 40 nM plasmid template 
and 40 nM/120 nM E. coli RNAP/σ70.  A lower concentration of RNAP and plasmid were used 
because the of the improved signal to noise from the modifications made to the DNA template.  
The deletion of the F1 ori downstream of the MGA repeats resulted in an approximately 1.8-fold 
increase in activity (Figure II-6, bottom and Table II-5), and resulted in an 11% decrease in plasmid 
size (358 bp). 
 
 Table II-5.  Fluorescence signal of plasmid-based transcription 
assay with varying DNA templates 
 
 
DNA Template 
Fluorescence 
(RFU) 
Signal Relative to 
pTZ18U-4xMGA 
 
 pTZ18U-4xMGA 2500 1  
 pTZ18U-4xMGA-lacCONS 2300 0.9  
 pTZ18U-4xMGA-lacUV5 4100 1.6  
 pTZ18U-4xMGA-
280bpDel 3200 1.3 
 
 pTZ18U-8Xmga 4600 1.8  
 pTZ18U-12xMGA 6900 2.8  
 
DNA Template 
Fluorescence 
(RFU) 
Signal Relative to 
pMGA12+F1ori 
 
 pMGA12+F1ori 2400 1  
 pMGA12 4200 1.8  
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Inhibition of E. coli WT RNAP by Rifampin 
 The inhibitory effect of rifampin on E. coli WT RNAP was evaluated using the plasmid-
based transcription assay with the DNA template pMGA12.  Rifampin was tested in triplicate at 
the concentrations specified in the Materials and Methods section.  The data were plotted (log 
rifampin concentration (M) vs. percent activity) and fit by nonlinear regression using Graph Pad 
Prism 6.  The IC50 value determined for rifampin was 5 nM (Figure II-7).  However, the amount of 
RNAP used in each reaction was 5 nM (the lowest concentration that could confidently be used).  
Under these conditions, it is possible that a 5 nM IC50 value may be at the limit of detection for 
the IC50 value, and the actual value may be less than 5 nM. 
 
Figure II-7.  Inhibition of E. coli WT RNAP by rifampin in plasmid-based transcription assay.  Assay was 
tested at 5 nM RNAP and 2.5 nM pMGA12 (n=3).  Data were fit by nonlinear regression using GraphPad 
Prism 6. 
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Discussion 
 Bacterial RNAP is a well-validated drug target, and is an important target in the treatment 
of tuberculosis.21,46,58  Issues of site-specific mutations to the M. tuberculosis RNAP have resulted 
in the emergence of drug-resistant cases of tuberculosis that are not susceptible to rifampin.  An 
assay amenable to high-throughput screening using the commercially available RiboGreen has 
been reported; however, in addition to the cost associated with the RiboGreen dye, it requires 
removal and purification of RNA from the DNA template since RiboGreen fluorescence is 
enhanced by binding to DNA as well as RNA.79  Previous assays to identify novel inhibitors of 
bacterial RNAP have used non-native substrates, which can be cost-prohibitive for high-
throughput screening.70,80 
A novel plasmid-based transcription assay has been developed that monitors the increase 
in fluorescence of malachite green upon binding to a 38-nucleotide RNA aptamer specific for 
triphenylmethane dyes.71  The MGA has previously been applied to detection of E. coli WT RNAP 
activity via rolling circle transcription of a small, circular, single-stranded DNA template.72  We 
adapted this approach to use the aptamer for detection of RNA transcribed from a double-
stranded DNA template.  After difficulties in detecting transcription by the MGA while using the 
initial plasmid template prepared (pTZ18U-4xMGA), the rolling circle transcription assay was 
utilized to recapitulate the assay used previously by Furukawa et al.  It was determined that the 
sensitivity of the MGA repeats was quite low compared to RiboGreen, and a higher sensitivity 
was required for the Synergy H1 Hybrid plate reader (Sensitivity = 150).  Based on the activity of 
E. coli WT RNAP with the original plasmid template (pTZ18U-4xMGA), the amount of plasmid and 
RNAP required for an HTS would be over 1 g and 100 mg, respectively.  Both of these numbers 
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were prohibitive for an HTS, therefore it was necessary to optimize the assay in order to increase 
the signal and allow for less RNAP and plasmid to be used per reaction. 
The plasmid pTZ18U-4xMGA was modified to decrease the size of the plasmid, increase 
the number of MGA repeats, and mutate the lacWT promoter to the lacUV5 promoter.  
Decreasing the size of the plasmid was advantageous because then a smaller amount (mass) 
would be required for an HTS.  The actual mass of plasmid required, and not number of plasmid 
molecules, is relevant because the capacities of DNA purification columns are based on the mass.  
Additionally, removal of the F1 ori resulted in a 1.8-fold increase in signal (Table II-5 and Figure 
II-6, bottom).  Mutation to the lacUV5 promoter instead of the lacWT promoter resulted in a 
plasmid that had higher activity in the transcription assay, as expected based on previous work 
studying promoter strength.78 
The iterative cloning technique successfully allowed for the insertion of multiple sets of 
MGA repeats, while regenerating the XbaI restriction site.  It was observed that the higher 
number of repeats were often instable in transformations, and it was not uncommon for plasmids 
with a large number of MGA repeats to lose some of these repeats, making it necessary to 
continually verify the plasmid sequence by DNA sequencing when making modifications or 
purifying more plasmid DNA.    The cells used for transformation, E. coli TOP10, have a mutation 
in recA, which is known to delete multiple repeats of DNA.81,82  However, there are RecA-
independent recombination events that affect repetitive DNA sequences.83,84  Therefore, it is 
likely that during the transformation and cell growth, additional MGA repeats can be lost through 
recombination mechanisms within the cell. 
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This assay was verified for detection of E. coli WT RNAP inhibition using the potent RNAP 
inhibitor rifampin.  The assay clearly monitored concentration-dependent inhibition and 
recapitulated (within a factor of 2) literature values for the inhibition of E. coli WT RNAP.56  It 
should be noted that the literature values for RNAP inhibition were obtained using an artificial 
DNA promoter in the ssDNA nanocircle, whereas the transcription assay used in this study utilized 
a double-stranded DNA template that requires promoter recognition and binding by an 
associated sigma factor. 
Conclusions 
 We have developed a robust plasmid-based transcription assay so that we can perform 
in vitro transcription assays with plasmid DNA purified from bacterial E. coli cells instead of a 
synthetic DNA template as is used in rolling circle transcription.  This assay requires a promoter 
and sigma factor for DNA binding and transcription initiation, whereas the rolling circle 
transcription assay is single-stranded and does not require a sigma factor or promoter 
recognition.  We are able to use the common lab reagent malachite green for RNA detection 
instead of the more expensive, proprietary RNA detection reagent RiboGreen.  We have 
optimized the plasmid DNA template so that it gives a strong signal and is amenable to high-
throughput screening. 
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Chapter III 
High-throughput Screen of Escherichia coli βS531L/β’V408G RNA Polymerase against 150,000 
Compound Library 
 Inhibition of bacterial RNA polymerase (RNAP) has been a cornerstone of tuberculosis 
(TB) treatment since the introduction of rifamycins in the 1960s.  Rifampin and other rifamycins 
are potent inhibitors of bacterial DNA-dependent RNAP.  Since its introduction in the 1960s, 
rifampin has been effectively used to treat TB and reduced the treatment from 18 to 9 months 
(now a 6-month treatment).21  However, rifampin and other rifamycins have several shortfalls 
including issues of resistance, flu-like syndrome at high doses, hepatotoxicity, and induction of 
cytochromes P450.46,85–87  It has been suggested that if higher doses of rifampin were tolerated, 
the treatment duration for tuberculosis could be shortened.88  Rifampin has issues of drug-drug 
interactions due to its induction of cytochromes P450 through the human pregnane X receptor, 
which is an issue due to the large TB population that is coinfected with HIV.  The issue of drug-
resistant cases of TB (MDR and XDR-TB), make it important to identify novel drugs for TB that are 
effective in treating drug-resistant strains of Mycobacterium tuberculosis (MTB). 
 Since there are several important shortfalls to rifampin and other rifamycins, it is 
necessary to identify novel scaffolds that can inhibit both wild-type (WT) and rifampin-resistant 
(RifR) strains of MTB RNAP.  Once a scaffold or set of scaffolds have been identified to inhibit MTB 
RNAP, they can be optimized for activity and assessed for their potential as an antibacterial agent. 
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 Even though there are several other known compounds that inhibit bacterial RNAP, these 
known compounds are not ideal for a variety of reasons as discussed in Chapter I (potency, 
permeability, etc.).  Previous screens to identify bacterial RNAP inhibitors have used radioactive 
nucleotides, non-native nucleotide analogs, or measured RNAP – sigma factor 
interactions.60,69,70,80  These assays are not ideal because they are either impractical (radioactive 
nucleotides), costly (non-native nucleotides), or detect a protein-protein interaction instead of 
transcription activity.   
 Studies have shown that the most clinically prevalent RifR mutation (βS450L, MTB 
numbering), has a fitness defect.89  In many clinical strains, this fitness defect is compensated for 
by specific secondary mutations in rpoC, where the most prevalent compensating mutation is 
V483G (MTB numbering) of the β’ subunit.90  In order to reflect what is likely the most prevalent 
RifR RNAP in drug-resistant strains of TB (MDR- and XDR-TB), the E. coli βS531L/β’V408G RNAP 
(corresponding to βS450L/β’V483G in MTB numbering) was used for the high-throughput screen. 
 The plasmid-based transcription assay developed and optimized (Chapter II) was adapted 
and implemented for the high-throughput screen (HTS).  The RifR E. coli RNAP (βS531L/β’V408G) 
was screened against a 150,000-compound library to identify compounds that inhibit RifR 
bacterial RNAP.  The compounds were screened against the E. coli homolog of the clinically 
prevalent MTB βS450L/β’V408G RNAP because they have a large sequence identity (~50%) and 
we were able to purify large quantities of highly active E. coli RNAP, while the MTB RNAP 
purification was of very low yield and not as active. 
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Materials and Methods 
Materials 
 All of the materials were the same as those specified in Chapter II.  The Qiagen Giga Kit 
was from Qiagen (Valencia, CA).  Oligonucleotide primers used in this study are listed in Table III-
1.  Plasmids used and prepared in this study are listed in Table III-2.  ProxiPlate-384 Plus F 
microplates were from PerkinElmer (Waltham, MA).  Fresh samples of selected compounds from 
the high-throughput screen were purchased from the vendors listed in Table III-3.  The pMTBRP 
plasmids and pVS10 E. coli RNAP expression plasmids for β subunit mutations D516V, H526Y, 
S531L were prepared by Dr. Suman Gill as previously described.56 
 A 150,554-compound library was screened at the Center for Chemical Genomics at the 
University of Michigan.  The library consisted of compounds from the Chemical Diversity set 
(ChemDiv-120,000 compounds), Maybridge HitFinder, MicroSource Spectrum, and NCC BioFocus 
libraries. 
Cloning, Preparation of E. coli βS531L/β’V408G RNAP Plasmid 
An expression plasmid for E. coli S531L RNAP with the compensatory mutation β‘V408G 
was prepared from the expression plasmid pVS10(S531L) as follows by Dr. Irosha Nawarathne.  
The wild-type E. coli rpoC gene was amplified from pVS10 using oligonucleotides ECrpoC-Fwd and 
ECrpoC-Rev, and subcloned using the TOPO Cloning Kit (pCR2.1-TOPO).  The compensatory 
mutation V408G (GTT – GGT) was introduced to rpoC via two-stage site-directed mutagenesis 
with complementary oligonucleotides ECrpoCMut-Fwd and ECrpoCMut-Rev.77  The mutant rpoC 
gene and pVS10 (S531L) were restricted with SbfI and SacII, and ligated with T4 DNA ligase to 
prepare pVS10 (S531L/V408G). 
37 
 
Table III-1.  List of oligonucleotides used 
Oligonucleotide Name 
(Restriction enzyme) Sequence, 5' - 3' (Restriction site underlined, if any) Length 
ECrpoC-Fwd GGTGGTCAGCGTTTCGGGGAGATGGAAGTGTGG 33 
ECrpoC-Rev GGGATCAGACGACCCACGATAACGTTCTCTTTCAGG 36 
ECrpoCMut-Fwd GCGAAGAAGCTGTCGGTTGGGATATCCTGGACGAAGTTATCCG 43 
ECrpoCMut-Rev CGGATAACTTCGTCCAGGATATCCCAACCGACAGCTTCTTCGC 43 
MTBrpoA-Fwd (BamHI) GAGAGGATCCTATGCTGATCTCACAGCGCCCCACCCTGTCC 41 
MTBrpoA-Rev (HindIII) 
GGGGAAGCTTGGCTAAAGCTGTTCGGTTTCGGCGTAGTCCTGCTCGTC
G 
49 
MTBrpoB-Fwd (NcoI) GAACCCCATGGCAGATTCCCGCCAGAGCAAAACAGCCGC 39 
MTBrpoB-Rev (BamHI) 
GATCGGATCCTTAATGGTGATGGTGATGGTGATGGTGATGGTGCGCA
AGATCCTCGACAC 
60 
MTBrpoC-Fwd (NdeI) GGGAGTCATATGCTCGACGTCAACTTCTTCGATGAACTCC 40 
MTBrpoC-Rev (EcoRV) CGTTATTTGAGGATATCCTAGCGGTAGTCGCTGTAGCCG 39 
MTBrpoZ-Fwd (NdeI) ATTACATATGAGTATCTCGCAGTCCGACGCG 31 
MTBrpoZ-Rev (KpnI) GAGTGGTACCGCTACTCGCCCTCGGTGTGC 30 
MTBsigA-Fwd (NcoI) 
GAAGGGGTGTCCATGGCAGCGACCAAAGCAAGCACGGCGACCGATG
AGCC 
50 
MTBsigA-Rev (MfeI) 
GCCTCGGCGGCAATTGTCAGTCCAGGTAGTCGCGCAGGACCTGTGAG
CGG 
50 
MTBrpoCMut-Fwd CCCCCAAGGCTGGGATGTGCTCG 23 
MTBrpoCMut-Rev CGAGCACATCCCAGCCTTGGGGG 23 
   
Cloning, Preparation of MTB RNAP Plasmids 
MTB RNAP expression vectors pACYCDuet-rpoA-rpoZ, pETDuet-rpoB-rpoC, and pRSF-SigA 
were prepared by Maxwell Stefan. The pACYCDuet-rpoA-rpoZ and pETDuet-rpoB-rpoC vectors 
were prepared using the same approach as Banerjee et al.91, amplifying and inserting the MTB 
genes using appropriate primers and restriction enzymes (Table III-1) from a construct previously 
prepared in our lab (pMTBRP-5).56  The sigA gene encoding MTB SigA was amplified from genomic 
DNA of M. tuberculosis H37RV using oligonucleotides MTBsigA-Fwd and MTBsigA-Rev.  pRSF-SigA 
was then prepared by restricting the sigA PCR fragment and pRSFDuet-1 with NcoI and MfeI, 
followed by phosphatase of pRSF vector, and ligation of the sigA gene and pRSF vector. 
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Expression vectors for mutant RNAPs (D435V, H445Y, S450L) were prepared by amplifying 
the mutant rpoB genes from previously prepared constructs (pMTBRP-6 thru 8) and inserting into 
pETDuet-rpoB-rpoC using the restriction enzymes NcoI and BamHI.56  The expression plasmid for 
MTB βS450L/β’V483G RNAP was prepared by mutating the rpoC gene subcloned in a TOPO vector 
to encode V483G (GTG – GGC) via two-stage site-directed mutagenesis using complementary 
oligonucleotides MTBrpoCMut-Fwd and MTBrpoCMut-Rev, then inserting into pETDuet-
rpoB(S450L)-rpoC.  pMCSG7-SigA was prepared previously.57  
Purification of E. coli RifR RNAPs 
 The E. coli D516V, H526Y, and S531L RNAPs were purified as described for E. coli WT RNAP 
in Chapter II, using the appropriate pVS10 expression vectors for each rpoB mutant.  E. coli 
βS531L/β’V408G RNAP used for the HTS was purified by Dr. Vadim Molodtsov (Penn State 
University) as described for E. coli WT RNAP with the following modifications.  Cultures of 3 L E. 
coli BL21(DE3) containing pVS10(S531L/V408G) were grown, induced, and harvested as 
described in Chapter II.  After precipitation by polymine P, the precipitate was resuspended to 
homogeneity with a glass rod in 30 mL of TGEB buffer (10 mM Tris-HCl, 5% glycerol, 0.1 mM 
EDTA, 5 mM β-ME, pH = 8.0 at 4°C) containing 1 M NaCl to solubilize RNAP, then centrifuged 
(8,000 x g, 20 min, 4°C) and further purified by ammonium sulfate precipitation and dialysis as 
described in Chapter II. 
The dialyzed RNAP was applied to a 50-mL cation-exchange Bio-Rex 70 column.  The 
column was washed with 2 column volumes (CVs) of TGEB containing 100 mM NaCl, and protein 
was eluted with 0.1 – 1 M NaCl gradient over 5 CVs.  The eluate was applied to a 10-mL Ni-NTA 
column equilibrated with TGEB containing 1 M NaCl at a flow rate of 0.5 mL/min.  The column 
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was washed with 4 CVs of same buffer, then 2 CVs of TGEB containing 50 mM NaCl and 10 mM 
imidazole.  RNAP was eluted with TGEB containing 50 mM NaCl and 100 mM imidazole.  The 
sample was applied to a 20-mL Q Sepharose column equilibrated with TGED (TGEB with 5 mM 
DTT instead of β-ME) containing 50 mM NaCl at a flow rate of 1 mL/min.  The column was washed 
with 2 CVs TGED, and RNAP was eluted with 0.1 – 1 M NaCl gradient over 10 CVs.  Eluate was 
concentrated at 4°C in a Vivaspin® 20 Centrifugal Concentrator to ~ 3 mL and applied to a HiLoad 
16/600 Superdex 200 equilibrated with RNAP storage buffer (10 mM Tris-HCl, 50 mM NaCl, 0.1 
mM EDTA, 5 mM DTT, pH = 8.0 at 4°C).  The protocol above was repeated until a sufficient amount 
of enzyme was obtained for the HTS (85 mg).  Eluate was collected and concentrated the same 
as above, then flash-frozen in nitrogen and stored at -80°C. 
Purification of E. coli σ70 
 The E. coli σ70 was purified by Dr. Vadim Molodtsov as follows.  E. coli BL21(DE3) 
containing pET15b-Sig70 (WT E. coli rpoD) were grown in 3 L 2xTY at 30°C until OD600 ~ 0.5, then 
induced with 1 mM IPTG and allowed to grow for an additional 2 hrs at 22°C.  Cells were harvested 
by centrifugation and resuspended in 30 mL σ70 lysis buffer (20 mM Tris-HCl, 0.4 M NaCl, 1 mM 
EDTA, 2 mM PMSF, 5 mM β-ME, 5% glycerol, pH = 8.0 at 4°C) then sonicated on ice.  The lysate 
was cleared by centrifugation (35,000 x g, 30 min, 4°C) and the supernatant (30 mL) was applied 
to a 10-mL Ni2+ column equilibrated with σ70 lysis buffer + 20 mM imidazole, then washed with 
20 CVs of the same buffer.  Protein fractions (25 mL) were eluted with 50 mL σ70 elution buffer 
(10 mM Tris-HCl, pH 8.0 at 4°C, 200 mM NaCl, 5% glycerol, 0.1 mM EDTA, 5 mM β-ME, 200 mM 
imidazole).  Next, the protein was diluted to reduce the concentration of NaCl to 100 mM and 
applied to a 5-mL Q Sepharose column equilibrated with σ70 elution buffer (without imidazole), 
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and a linear gradient of 0.1 – 0.6 M NaCl over 20 CVs.  Fractions containing σ70 were determined 
by SDS-PAGE, combined (60 mg in 20 mL) and flash-frozen in liquid N2. 
Table III-2.  List of plasmids used in this study 
Plasmid Name Description Reference 
pMGA12 
pMGA12+F1ori with 358 bp deletion downstream of MGA 
repeats 
This study 
pVS10 Expression vectors for E. coli RNAP core enzymes (56) 
pET15b-Sig70 Expression vector for E. coli Sig70 
K. Murakami 
(unpublished) 
pMCSG7-SigA Expression vector for MTB SigA (57) 
pMTBRP-5 thru 8 Original constructs for MTB RNAP Expression (56) 
pACYCDuet-rpoA-
rpoZ 
Dual expression vector for MTB RNAP α and ω subunits This study 
pETDuet-rpoB-
rpoC 
Dual expression vector for MTB RNAP β and β' subunits This study 
pRSF-SigA Expression vector for MTB SigA This study 
 
   
Purification of MTB RNAPs 
 MTB RNAP holoenzymes (WT, D435V, H445Y, S450L, and S450L/V483G) were purified as 
follows.  E. coli BL21(DE3) containing the expression vectors pETDuet-rpoB-rpoC, pACYCDuet-
rpoA-rpoZ, and pRSF-SigA were grown at 37°C in 1 L 2xTY with carbenicillin, kanamycin, and 
chloramphenicol until OD600 = 0.4 – 0.6.  Protein expression was induced with 0.5 mM IPTG and 
grown for 16 to 20 hrs at 16°C.  Cells were harvested, and the protein was purified and stored as 
described in Chapter II for E. coli WT RNAP, using TGED containing 300 mM NaCl for gel filtration 
with the Sephacryl S-300 HR column. 
Purification of MTB SigA 
 E. coli BL21(DE3) containing pMCSG7-SigA were grown in 2 L 2xTY at 37°C until OD600 = 
0.4 – 0.6, then expression was induced with 1 mM IPTG and grown at 16°C for 16 – 20 hrs.  Cells 
were pelleted and resuspended in σ70 lysis buffer and supplemented with 2 mM PMSF.  Cells 
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were sonicated and lysate was cleared by centrifugation (21,000 x g, 40 min, 4°C).  Supernatant 
was incubated with 2 mL Ni-NTA agarose and incubated at 4°C with shaking for 1 hr.  Mixture 
was then applied to a column and washed as follows: 5 CVs – σ70 lysis buffer, 8 CVs – σ70 lysis 
buffer + 15 mM imidazole, 10 CVs – σ70 lysis buffer + 100 mM imidazole.  Eluted protein was 
concentrated using a 10 kDa MWCO Amicon Ultra-15 Centrifugal Filter Unit, filtered, and applied 
to a HiPrep 16/60 Sephacryl S-200 HR equilibrated with TGED containing 200 mM NaCl.  Protein 
was pooled and concentrated, then flash-frozen and stored at -80°C. 
Preparation of Materials for High-Throughput Screen and Transcription Assays 
Large quantities of pMGA12 were generated for the screen using a Qiagen Giga Kit, 
preparing Buffer P1 without RNase A and regenerating the QIAGEN tip-10000 columns as 
previously described.92  NTPs were prepared at 100 mM, then adjusted the pH of each NTP to 7.5 
before preparing a 25 mM NTP mix by adding equal amounts of each NTP.  Buffers used for the 
screen were prepared with certified DNase/RNase free components and Milli-Q water. 
Time Course Transcription Assay 
 Reactions of 100 µL for each E. coli RNAP were prepared as follows.  In each tube, 48 µL 
of a 2x E. coli reaction buffer solution [80 mM Tris-HCl (pH = 7.5 at 23°C), 100 mM KCl, 20 mM 
MgCl2, 0.02% Triton X-100, 16 mM DTT, 20 nM pMGA12, 1 mM NTPs] was added, 2 µL of DMSO, 
followed by 48 µL of a 2x RNAP solution (80 nM RNAP, 240 nM σ70).  Reactions were incubated 
at 37°C for 3.5 hrs.  Starting at time = 0 min, 10 µL aliquots were removed from the reaction 
mixture every 30 min and quenched in 40 µL ice cold Milli-Q water in a 96-well plate (Corning 96-
Well Half Area Black Flat Bottom Polystyrene NBSTM microplate).  Then, 50 µL of 150 µM MG in 
water was added to each well and incubated on ice for 10 min before measuring fluorescence at 
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excitation and emission wavelengths of 628 and 660 nm, respectively.  Raw fluorescence values 
were plotted against time for each enzyme tested. 
 MTB RNAPs were tested in the same manner, using a 2x MTB reaction buffer solution (40 
mM Tris-HCl (pH = 8.0 at 37°C), 20 mM MgCl2, 300 mM potassium L-glutamate, 15% glycerol, 20 
nM pMGA12, 1 mM NTPs), and used MTB SigA instead of E. coli σ70.   
High-throughput Bacterial Transcription Assay 
The transcription assay described above was modified to 384-well plate format, with a 
reaction volume of 20 µL.  A 2x E. coli reaction buffer was added (10 µL) to each well of 384-
shallow well microplates (ProxiPlate-384 Plus F) using a multidrop dispenser (Thermo Scientific, 
Waltham, MA).  Compounds or DMSO were then added (20 µM final, n = 1, 0.2 µL) to the 
appropriate wells using a Biomek FX HDR pintool instrument (Beckman, Fullerton, CA).  TGED 
containing 50 mM NaCl and 0.01% Triton X-100 was added (10 µL) to the appropriate wells for a 
positive control via multidrop dispenser.  A 2x RNAP solution (80 nM βS531L/β’V408G E. coli 
RNAP core, 240 nM E. coli σ70 in TGED containing 50 mM NaCl and 0.01% Triton X-100 was added 
to the appropriate wells (10 µL) via multidrop dispenser for a reaction volume of 20 µL.  The 
plates were incubated at 37°C for 2 hrs, then placed on ice for 10 min.  A solution of 150 µM 
malachite green was added (5 µL) to each well.  The plates were incubated on ice for 10 min 
before measuring fluorescence with an EnVision Multilabel plate reader (PerkinElmer) using a 
Cy5 620/10 filter for excitation and a LANCE 665/7.5 filter for emission. 
Reconfirmation and Counter Screens 
Compounds identified from the primary HTS were tested against a series of control 
screens.  First, compounds were retested (n = 3) in the assay following the protocol above, except 
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compounds were added to empty plates using a mosquito X1 (TTP Labtech) prior to addition of 
buffer and RNAP solutions.  These compounds were also tested for interference of MG-MGA 
fluorescence by adding 20 µL of a reaction mixture (1x E. coli reaction buffer solution and 1x E. 
coli RNAP solution incubated at 37°C for 2 hrs) into plates containing the compounds, followed 
by addition of malachite green (5 µL, 150 µM).  After 10 min on ice, the fluorescence was 
measured at excitation and emission wavelengths of 620 and 665 nm, respectively (EnVision 
plate reader).  Compounds that reconfirmed and did not inhibit MG-MGA fluorescence were 
tested for concentration-dependent inhibition.  For the concentration-response study (n=2), the 
concentration of the compounds was varied using two-fold serial dilutions (0.78 – 100 µM final), 
and tested following the screening protocol described above, adding the compounds to empty 
plates using the mosquito X1. 
Data Analysis 
Active compounds from the initial high-throughput screen were defined as compounds 
that decreased fluorescence signal more than or equal to three times the standard deviation 
(s.d.) of the negative controls (all analyses were calculated on a plate-by-plate basis) and resulted 
in greater than or equal to 20% fluorescence inhibition.  Compounds that the NIH does not allow 
in their screening collection due to reactivity or known toxic substituents (black flags), and 
compounds with chemical motifs that tend to be highly reactive or highly toxic and nonspecific 
(red flags) were excluded.93  Compounds that hit in more than 30% of screens previously run at 
the CCG were also excluded. 
Compounds that passed these initial selection criteria were retested (n=3) and screened 
for false positives due to inhibition of fluorescence of MGA bound malachite green.  Compounds 
44 
 
that inhibited fluorescence of MGA-bound malachite green (n=3) more than 25% were excluded.  
(Note that two rows on each plate used a less stringent cutoff of 45% fluorescence inhibition due 
to a partial clog in one tube of the multidrop dispenser cassette for MG, resulting in a lower 
average fluorescence for these wells.)  Remaining compounds with fluorescence inhibition more 
than or equal to three times the s.d. of the negative controls in at least 2 wells (n=3) were tested 
for concentration-dependent inhibition.  Compounds that inhibited E. coli βS531L/β’V408G RNAP 
in a concentration-dependent manner (determinable IC50 or displayed concentration-dependent 
trend) were considered hits from the high-throughput screen.  Data were fit by nonlinear 
regression to Eq. (1) where M0 = log of compound concentration, M1 = log of IC50, M2 = hill slope, 
M3 = lower limit of the curve, and M4 = upper limit of the curve. 
 (1) 𝑦 = 𝑀3 +
(𝑀4−𝑀3)
(1+10(𝑀0−𝑀1)×𝑀2)
 
 
Reconfirmation of Hits 
Fresh samples of compounds identified as hits were ordered from commercial vendors 
for a reconfirmation concentration-response study.  This study was done in the same format as 
the initial concentration-response study, testing the fresh compounds for activity against E. coli 
βS531L/β’V408G RNAP.  The fresh compounds were then tested against a panel of E. coli and 
MTB RNAPs (10 total, Table III-3). The compounds were tested against each enzyme using the 
screening protocol above (using 2x MTB reaction buffer for MTB RNAPs). Two-fold serial dilutions 
of compounds were dispensed in duplicate from a mother plate using the pintool device.  The 
mother plate concentrations ranged from 20 to 0.01 mM, giving final compound concentrations 
of 200 to 0.1 μM in the transcription reactions.  Rifampin was tested in the same manner, using 
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a mother plate to give final compound concentrations of 1280 to 0.625 nM in the transcription 
reactions. 
Results 
Plasmid Preparation and Expression of E. coli and MTB RNAPs 
 To evaluate the inhibition of compounds identified from the HTS against a panel of 
bacterial RNAPs (E. coli and MTB, WT and RifR), plasmid constructs for E. coli βS531L/β’V408G 
RNAP and MTB RNAPs were prepared to allow for the expression and purification of each RNAP 
of interest.  A pVS10 construct previously prepared for expression of E. coli βS531L RNAP was 
modified by mutagenesis of the rpoC gene to encode the compensatory mutation V408G, 
resulting in the mutant vector pVS10(S531L/V408G).56  The expression system for MTB RNAP was 
prepared as described by Banerjee et al. to give the plasmid vectors pACYCYDuet-rpoA-rpoZ and 
pETDuet-rpoB-rpoC.91  The mutated genes for the MTB RNAPs D435V, H445Y, and S450L were 
subcloned individually to give mutant vectors for each on the pETDuet-rpoB-rpoC plasmid 
construct.  The compensatory mutation β’V483G was subcloned onto pETDuet-rpoB(S450L)-rpoC 
for preparation of the expression vector pETDuet-rpoB(S450L)-rpoC(V483G).  The E. coli and MTB 
RNAPs were successfully purified and presence of subunits was verified by SDS-PAGE.  The 
concentrations of the proteins were determined by the Bradford protein assay, and the activity 
of the RNAPs were confirmed using the plasmid-based transcription assay (data not shown). 
Time Course Transcription Assay 
 The linearity of transcription as a function of time was tested for each enzyme purified to 
verify the length of time for the end-point detection transcription assay.  It was important to 
ensure that each enzyme activity was still linear after the 2-hr detection time used in the 
46 
 
transcription assay in order to be able to accurately determine and compare inhibition between 
compounds and across enzymes.  The transcription activity of E. coli βS531L/β’V408G RNAP used 
for the HTS and its MTB homolog are shown in Figure III-1.   
 It was determined that the RNAP transcription activity was linear beyond 2 hrs (tested to 
3 hrs for each enzyme) for each enzyme (data only shown for one representative enzyme for each 
species, E. coli and MTB).  This indicates that the two-hour reaction for end-point detection is 
sufficient when using the plasmid-based transcription assay to detect RNAP activity and the effect 
of compounds on enzyme activity. 
Adaptation for High-Throughput Screen 
 The plasmid-based transcription assay was adapted for an HTS by decreasing the reaction 
size from 50 µL to a 20 µL reaction.  The transcription reaction was tested in various 384-well 
plates (Corning 4514, Greiner 784076, Greiner 784900, and ProxiPlate-384 Plus F) to determine 
Figure III-1.  Transcription activity of E. coli and MTB RifR RNAP with compensatory mutation.  E. coli 
βS531L/β’V408G and MTB βS450L/β’V483G RNAPs were tested in the plasmid-based transcription assay, 
with 10 µL aliquots being quenched every 30 min.  Fluorescence detection by malachite green (Ex/Em = 
628/660 nm). 
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the optimal plate for screening (data not shown).  It was determined that the ProxiPlate resulted 
in the largest signal for transcription detection, and was therefore chosen as the assay plate for 
the HTS.  The transcription assay was tested at the high-throughput screening facility using all 
the liquid handling equipment, testing the positive and negative controls (no RNAP and DMSO, 
respectively).  An assay plate with E. coli βS531L/β’V408G RNAP containing the negative and 
positive controls at a ratio of 50:50 were tested to determine the suitability of the assay for an 
HTS (Figure III-2).  The suitability of the assay for an HTS was determined by calculating the Z-
factor (Z’) of the assay when conducted using the liquid handling equipment.  The Z’ is a 
dimensionless, statistical characteristic for an HTS assay that can be utilized for comparison and 
evaluation of the quality of an assay.94  It is calculated from the means and s.d. of both the 
positive and negative controls of the assay, using Eq. (2) where σp and σn represent the s.d. of the 
positive and negative control (respectively) and µp and µn represent the mean of the positive and 
negative control (respectively). 
Figure III-2.  Controls of transcription assay with E. coli βS531L/β’V408G RNAP in 384-well plate format for 
high-throughput screen. Positive control values (no RNAP) are at the bottom in blue, and negative control 
values (RNAP, DMSO) are at the top in orange. Z’ was determined using Eq. (2). 
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 (2)   𝑍′ = 1 −
3(𝜎𝑝+𝜎𝑛)
|µ𝑝−µ𝑛|
 
 A Z’ > 0.5 is considered suitable for an HTS, whereas Z’< 0.5 can have an increased 
propensity for false positives and false negatives.  False positives and negatives are compounds 
that are incorrectly assigned as active or inactive.  This can be due to assay interference, 
detection interference, or the uncertainty/error associated with the assay.  The Z’ for the assay 
using the test plate in Figure III-2 was determined to be 0.70, indicating that the transcription 
assay is highly suitable for an HTS. 
High-Throughput Screen 
 The ~150,000 compound HTS was carried out using the E. coli βS531L/β’V408G RNAP with 
pMGA12.  The average Z’ per plate in the primary screen was calculated to be 0.86 across the 
plates tested in the screen.  Figure III-3 is an inhibition plot for the primary screen, showing the 
percent inhibition values (calculated on a plate-by-plate basis) for each of the compounds tested.  
The 20% inhibition line (Figure III-3, blue) was one of the selection criteria for the initial HTS 
triage. 
Figure III-3.  Inhibition plot of 150,554 compounds tested in the HTS against E. coli βS531L/β’V408G RNAP.  
Compound number is an arbitrary reassignment of CCG compound numbers starting at 1 for visualization 
purposes.  Positive control values are green, negative control values are red, and sample values are black.  
Blue line indicates 20% inhibition. 
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HTS Hit Identification 
 A summary of the triage of the HTS is shown in Figure III-4.  The primary screen identified 
1738 compounds (1.2% hit rate) that met the initial selection criteria of percent inhibition, 
promiscuity, and potential toxicity and reactivity.  The 1738 compounds were then tested in two 
different control screens.  The compounds were retested in triplicate and tested for inhibition of 
the MG-MGA fluorescence signal (in triplicate).  This resulted in the identification of 307 
compounds that reconfirmed in triplicate and did not inhibit the MG-MGA fluorescence signal.  
These 307 compounds were then tested for concentration-dependent inhibition, which identified 
234 compounds that displayed concentration-dependent inhibition of E. coli βS531L/β’V408G 
RNAP transcription, with 190 compounds having a determinable IC50 (IC50 < 100 µM, the highest 
Figure III-4. Flow chart of selection criteria for high-throughput screen.  *A less stringent cutoff (45%) was 
used for two rows of the 384-well plates (see Results: Data Analysis). 
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concentration tested).  Figure III-5 contains a waterfall plot of the IC50 values for the compounds 
that showed concentration-dependent inhibition.  With the help of Drs. Paul Kirchhoff and Hollis 
Showalter, the compounds were further triaged based on their potential toxicity, novelty, 
redundancy, and commercial availability. This resulted in the selection of 63 compounds that fell 
into 18 different structural scaffold clusters to be ordered. 
Reconfirmation of Hit Compounds 
 Rifampin was tested for inhibition of E. coli WT RNAP using the liquid handling equipment 
to validate the accuracy of the instrumentation, particularly the Biomek FX HDR pintool 
instrument, since using a pintooler is an atypical way to set up concentration-response assays.  
In parallel, transcription reactions testing inhibition of E. coli WT RNAP by rifampin in a 
concentration-dependent manner were setup either 1) by hand using multipipettes or 2) using 
the HTS liquid handling equipment.  Concentration-response curves for the two experiments 
were analyzed by nonlinear regression.  As seen in Figure III-6, the two experimental methods 
resulted in similar concentration-response curves, indicating the accuracy of the pintooler when 
setting up concentration-response curves. 
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Figure III-5. Waterfall plot of IC50 values determined against E. coli βS531L/β’V408G of 234 compounds 
identified during HTS triage. 
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 Fresh samples of the 63 compounds were purchased and re-tested for activity.  Of the 63 
compounds, 30 compounds were inactive against E. coli βS531L/β’V408G RNAP; however, only 
three were eliminated due to the other 27 inactive compounds being members of structural  
clusters that contained active analogs.  The 60 compounds were then tested for activity against 
a panel of E. coli and the corresponding MTB RNAPs: WT, 3 different RifR mutants (βD516V, 
βH526Y, βS531L – E. coli numbering), as well as the MTB double mutant with a compensatory 
mutation (βS450L/β’V483G).  The IC50 values of the compounds against these RNAPs ranged from 
5 µM to >200 µM, and most of the compounds had similar values across the RNAP enzymes 
tested.  The individual IC50 values for the most active compounds against each enzyme are in 
Table III-3. 
Discussion 
 M. tuberculosis RNAP is a well-validated target for the treatment of tuberculosis; 
however, target-based mutations conferring resistance to rifampin have resulted in a large 
number of RifR strains in clinical isolates.  The potent sterilizing activity (i.e., bactericidal against 
Figure III-6.  Comparison of compound transfer methods for transcription assay inhibition studies.  Biomek 
FX HDR pintooler was used to transfer 0.2 µL of varying concentrations of rifampin in DMSO. 
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both active and latent MTB) of rifampin against WT MTB indicates that RNAP is still a promising 
target for the treatment of RifR MTB if the rifamycin resistance can be circumvented.  An assay 
that monitors the increase in fluorescence of malachite green upon binding to an RNA aptamer 
has been adapted for high-throughput screening.  Obtaining quantities of M. tuberculosis RNAP 
sufficient for a high-throughput screen has been prohibitive.  However, the E. coli RNAP can be 
obtained in sufficient quantities, has greater activity, and is more stable than the MTB RNAP.  We 
have shown that the E. coli RNAP is a reasonable model for the MTB RNAP56 and we have solved 
the X-ray crystal structure of the E. coli RNAP alone and in complex with rifamycin derivatives 
that we have designed.95,96  This provides us the potential to determine the three-dimensional 
structure of the RNAP complex with any novel RNAP inhibitor that we find which has sufficient 
affinity. 
An HTS of 150,554 small molecules was carried out against E. coli RNAP βS531L/β’V408G 
(Figure III-3) using the plasmid-based in vitro transcription assay.  As shown in Figure III-4, the 
concentration-response, control screening, and triage for potential toxicity, novelty, redundancy, 
and commercial availability resulted in the selection of 63 compounds to order. 
The reconfirmation assays were setup using the Biomek pintooler for multiple reasons.  
First, it can dispense small volumes of compound quickly from a stock plate to an assay plate.  
Second, unlike the mosquito X1, the Biomek pintooler can transfer compounds very quickly 
(minutes instead of hours) and can easily be used to set up multiple plates containing the same 
set of compound dilutions.  As was shown with rifampin against the E. coli WT RNAP, the pintooler 
can accurately dispense compound dilutions and replicate the inhibition obtained through 
traditional pipette transfer techniques (Figure III-6). 
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 IC50 values are averages of WT, S531L, D516V, H526Y, βS531L/β’V408G 
(E. coli numbering).  See Table III-3 for individual IC50 values. 
 
Table III-4.  Compounds with similar activity across WT and RifR RNAP 
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Table III-5.  Compounds with reduced activity against E. coli H526Y RNAP (cluster 6) 
aE. coli βS531L/β’V408G RNAP 
bIC50 values are averages of WT, S450L, D435V, H445Y, βS450L/β’V483G.  See Table III-3 
for individual MTB IC50 values. 
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The fresh samples were screened against a panel of E. coli and the corresponding MTB 
RNAPs: wild-type, 3 different RifR mutants (D516V, H526Y, S531L – E. coli numbering) as well as 
the double mutant (βS531L/β’V408G – E. coli numbering).  The IC50 values of the compounds 
against these RNAPs ranged from 5 to > 200 µM (data not shown).  With the exception of cluster 
6, discussed below, we selected scaffolds that do not show any large (>10-fold) differential in IC50 
values across the panel of WT and RifR RNAP mutants tested, as these would seem to be more 
promising as they are likely to be binding outside of the rifampin resistance determining region, 
hence lacking cross-resistance with RifR RNAPs. 
Encouragingly, 9 of the 63 compounds (Table III-4) had similar IC50 values across the panel 
of RNAP enzymes tested, indicating that they are active against RifR mutants.  Cluster 1, the 
cyanopyrimidine scaffold was identified as one of the more potent scaffolds, with IC50 values 
ranging from 5 to 40 µM. 
Another group of compounds (Table III-5, cluster 6, pyrazolopyrimidines) showed 
comparable activity across most of the E. coli RNAPs with the exception of H526Y.  A recent crystal 
structure of E. coli H526Y RNAP shows significant conformational changes in the rifamycin 
binding pocket relative to the wild-type, D516V, and S531L RNAPs.97  This suggests that these 
compounds may bind in the rifamycin binding pocket, but their much smaller size relative to 
rifampin allows them to bind to the D516V and S531L RifR mutants.  As precedence, the RNAP 
inhibitor sorangicin A has been shown to bind in the rifamycin binding pocket and encounter 
partial resistance by some RifR mutants and complete cross-resistance by other RifR mutants.62,98  
Xu et al. showed that E. coli H526Y RNAP had complete resistance to sorangicin A while mutants 
D516N and S531F, and other residues, showed only partial or no resistance.99  Compound 186618 
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of cluster 1 was however active against all of the RNAP enzymes tested, indicating a potential for 
activity against E. coli H526Y RNAP and MTB RNAPs. 
Two compounds that are more potent against MTB RNAPs relative to E. coli RNAP (Table 
III-4) were identified.  Compound 257177 is in the same cluster as 123513 (Table III-4, cluster 4), 
but has a significantly different activity profile.  Compound 257177 is ~10-fold less active against 
E. coli RNAP than 123513.  We cannot make any significant correlations between the structures 
and activities of these two compounds; however, these differences are noteworthy for potential 
future structure activity relationship studies in optimizing activity for MTB (or E. coli) RNAP.  
Compound 145060 showed no significant activity against E. coli RNAP in the follow up assays, 
and only modest activity against MTB RNAPs (>50 µM). 
Eleven of the fifteen compounds (Table III-4) exhibited very similar activity against WT 
and RifR RNAPs, providing proof of principle that novel RNAP inhibitors can be found that are 
insensitive to the RifR mutations.  While the in vitro activities of these analogs are very modest 
(low micromolar at best), these compounds represent an initial structure-activity relationship 
(SAR) probe using only commercially available HTS hits.  A hit-to-lead campaign involving iterative 
design, synthesis and testing will very likely identify much more potent inhibitors of WT and RifR 
MTB RNAP. 
Conclusions 
 We have adapted a plasmid-based transcription assay for use in a high-throughput 
screen, and screened 150,000 compounds against a RifR bacterial RNAP (E. coli βS531L/β’V408G).  
The high-throughput screen identified 234 compounds that inhibited E. coli βS531L/β’V408G 
RNAP in a concentration-dependent manner.  After further triage, we purchased 63 compounds 
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for further testing.  The purchased compounds were tested against both WT and RifR mutants 
(D516V, H526Y, S531L – E. coli numbering) of E. coli and MTB RNAPs as well as MTB 
βS450L/β’V483G RNAP.  We have identified 15 compounds of interest that were active against 
either E. coli or MTB RNAPs, or both. 
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Chapter IV 
In vitro Evaluation of Hit Scaffolds Identified from High-Throughput Screen 
 Bacterial RNA polymerase (RNAP) is an antibacterial target of interest for several reasons.  
Bacterial RNAP is an essential enzyme that has been an important target for the treatment of 
tuberculosis (TB) since the introduction of rifamycins in the 1960s.  The primary mechanism of 
bacterial resistance arises from site-specific mutations in the rifampin binding site.  It has already 
been shown that potent compounds can be identified that do not have cross-resistance to 
rifampin, as seen with GE23077.63  Therefore, in order to identify a potent small molecule 
inhibitor of wild-type (WT) and rifampin-resistant (RifR) Mycobacterium tuberculosis (MTB) RNAP, 
a high-throughput screen (HTS) was performed against the RifR E. coli RNAP homolog 
βS531L/β’V408G RNAP.  Initial triage resulted in the purchase and evaluation of 63 compounds 
identified from the HTS, identifying 15 compounds with promising activity against a panel of E. 
coli and/or MTB RNAPs. 
 Scaffolds identified from the HTS (Chapter III) were further investigated for their potential 
as potent inhibitors of bacterial RNAP.  Since the compounds identified from the screen have low 
activity (low micromolar at best), the scaffolds were first evaluated for potential structure-
activity relationships (SAR) using commercially available analogs.  This was done to determine if 
there are changes in their activity correlated with changes in the compound structure – which 
would indicate that there is a distinct binding site and that binding affinity and inhibition may be 
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improved in a hit-to-lead campaign.  In addition, select compounds of interest were synthesized 
to further validate the structure and activity of the purchased compounds. 
 Aromatic nitriles have been reported to form covalent bonds with enzymatic cysteines 
and lead to irreversible covalent inhibition depending on their electrophilicity (Figure IV-1).100  
Inhibitors that covalently interact with a cysteine have been developed for targets such as kinases 
with clinical success.101–103  However, there are potential issues associated with covalent 
inhibitors, such as non-specificity.104  In order to determine if the cyanopyrimidine scaffold that 
we identified in our HTS is a false positive and non-specifically interacting with bacterial RNAP, 
the scaffold was investigated for 1) essentiality of nitrile for inhibition, 2) reversibility of 
inhibition, and 3) cysteine adduct formation.  The results of these experiments were examined 
to determine whether the cyanopyrimidine scaffold is a specific inhibitor of bacterial RNAP and 
a potential candidate for further optimization as an anti-TB agent. 
Materials and Methods 
Materials 
 All of the materials were the same as those specified in Chapter II.  Compound analogs 
purchased were from ChemDiv or Vitas-M, unless otherwise specified.  Synthetic 
oligonucleotides purchased from Invitrogen are listed in Table IV-1.  A Shimadzu LC-MS was used 
Figure IV-1.  Covalent interaction of nitrile with L-cysteine to form cysteine adduct. 
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for nitrile reactivity assay analysis.  pMGA4-Ec and pMGA4-Mtb were prepared as described for 
pMGA12 in Chapter III.  E. coli and MTB RNAPs were prepared as described in Chapter III. 
 Table IV-1.  List of oligonucleotides used for FID Assay  
 Oligonucleotide 
Name                 
Sequence, 5' - 3' Length 
 
 
FID-lacUV5 Top 
TTAGGCACCCCAGGCTTTACACTTTATGCTTCC
GGCTCGTATAATGTGTGGAATTGTGAG 
60 
 
 
FID-lacUV5 Bottom 
CTCACAATTCCACACATTATACGAGCCGGAAG
CATAAAGTGTAAAGCCTGGGGTGCCTAA 
60 
 
 
   
 
 Fluorescent Intercalator Displacement Assay 
 Binding of compounds to DNA was determined by fluorescent intercalator displacement 
(FID).  A 60-bp FID-lacUV5 probe was used for this study.  The FID-lacUV5 probe was hybridized 
by mixing the top and bottom oligonucleotides (Table IV-1) 1:1 after suspending in TE/NaCl buffer 
(10 mM Tris-HCl, 1 mM EDTA, 50 mM NaCl, pH = 8.0).  The top and bottom oligonucleotides were 
annealed in a thermocycler by heating at 94°C for 2 min, followed by 70°C for 2 min, then was 
allowed to slowly cool to room temperature.  The assay was conducted in triplicate as previously 
described.105  In brief, 70 μL of 64.3 μM ethidium bromide in Tris/NaCl buffer (0.1 M Tris HCl, 0.1 
M NaCl, pH = 8.0) was added to all wells of a black, half-area, 96-well plate.  Then, 10 μL of 
TE/NaCl buffer (background fluorescence control) or 15 μM FID-lacUV5 probe in TE/NaCl buffer 
were added to the appropriate wells, followed by addition of 20 μL test compound in 10% DMSO 
Tris/NaCl Buffer (10% DMSO Tris/NaCl Buffer for 100% fluorescence control).  The concentrations 
tested ranged from 12.5 to 100 μM.  The plates were protected from light and allowed to 
equilibrate for 30 min followed by fluorescence measurement (Ex/Em = 545/595 nm).  The 
background fluorescence was subtracted from all data and % fluorescence inhibition was 
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calculated according to Eq. (1) where Ftest = average fluorescence obtained in presence of test 
compound and F100% = the average fluorescence of the 100% fluorescence control). 
(1)            % 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =  
𝐹100%−𝐹𝑡𝑒𝑠𝑡
𝐹100%
×100 
 
Minimal Inhibitory Concentrations against virulent M. tuberculosis and Cytotoxicity 
 Minimal inhibitory concentrations (MICs) of compounds against M. tuberculosis H37RV 
were determined by Baojie Wan at the University of Illinois at Chicago as previously described 
using the Microplate Alamar Blue Assay (MABA) and Low-Oxygen Recovery Assay (LORA).106  
Cytotoxicity of compounds were determined by Baojie Wan against Vero cells using an MTS assay 
as previously described.107 
Plasmid-Based Transcription Assay 
 Plasmid-based in vitro transcription assays to determine compound IC50 values were 
performed as described in Chapter II for rifampin with the following modifications.  The 
concentration of pMGA12 or pMGA4-Ec (Figure IV-2) was 80 nM in the 2x E. coli reaction buffer, 
and E. coli WT RNAP and σ70 were 40 nM and 160 nM (respectively) in the 2x RNAP solution.  
Reactions were incubated at 37°C for 90 min before quenching in 150 µM malachite green (MG).  
Compound concentrations tested were 3.12 to 400 µM (triplicate), unless otherwise specified. 
MTB RNAPs were tested in the same fashion, using a 2x MTB reaction buffer solution (40 
mM Tris-HCl (pH = 8.0 at 37°C), 20 mM MgCl2, 300 mM potassium L-glutamate, 15% glycerol, 20 
nM pMGA12, 1 mM NTPs) with 80 nM pMGA12 or pMGA4-Mtb (Figure IV-2) plasmid.  The 
concentration of the 2x RNAP solution was 80 nM MTB RNAP and 240 nM SigA. 
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The purchased compounds and synthesized compounds were both tested in this plasmid-
based transcription assay as described.  Data were analyzed and IC50 values were determined as 
described in Chapter II, normalizing fluorescence values to percent activity and fitting data by 
nonlinear regression. 
Assay to Detect Irreversibility of RNAP Inhibition 
 Compounds were tested for reversible inhibition of RNAP according to the scheme in 
Figure IV-3.  Compounds (200 µM) or DMSO were incubated with E. coli WT RNAP (2 µM) at 37°C 
for 30 minutes in 1x E. coli reaction buffer without NTPs (20 µL).  After incubation, 4 µL of the 
mixture was diluted 100-fold with 1x E. coli reaction buffer, diluting compounds 100-fold to 2 
µM, and the enzyme to 20 nM.  Aliquots of 47 µL were added to a 96-well plate, followed by the 
addition of 2 µL compound or DMSO (in triplicate).  Reactions were initiated by adding 1 µL of 5 
Figure IV-2.  Plasmid map of DNA template containing terminator sequences and E. coli or MTB 
promoter.  Plasmid containing E. coli rrnB1 promoter (pMGA4-Ec) is 3156 bp.  Plasmid 
containing MTB rrnA3 promoter (pMGA4-Mtb) is 3179 bp. 
 
65 
 
mM NTPs.  After incubation at 37°C for 1.5 hours, activity was detected by fluorescence (Ex/Em 
= 628/660nm) after addition of 50 µL of 150 µM MG. 
Nitrile Reactivity Assay 
 The four cyanopyrimidine compounds (cluster 1 – 257176, 257180, 257181, 257182) 
identified from the high-throughput screen were tested for reactivity with L-cysteine as well as 
two control compounds, CCG-257084 and 5-bromopyrimidine-2-carbonitrile.  CCG-257084 and 
5-bromopyrimidine-2-carbonitrile have been shown to either not form or extensively form a 
cysteine adduct, respectively.100  Compounds (or DMSO for background control) were incubated 
with L-cysteine to determine their ability to form adducts with L-cysteine, similarly to previously 
described for other aromatic nitrile compounds.100  In short, reaction mixtures of 500 µL were 
prepared containing 200 µM compound, 2 mM L-cysteine, and 50 mM Na2HPO4 (pH = 7.4), then 
incubated at 37°C for 30 min.  The reaction mixtures were diluted in 1 mL of methanol, followed 
Figure IV-3.  Overview of transcription assay used to detect reversibility of inhibition. 
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by injection of 30 µL onto an LC-MS instrument (Shimadzu) pre-equilibrated with 10:90 
acetonitrile:water (v/v).  The injected sample was then eluted over a 15-minute gradient from 
10% to 90% acetonitrile (v/v).  Pure compounds diluted in 500 µL water and 1 mL methanol were 
also injected and analyzed as negative controls to help identify the original compound peak and 
potential contaminants or background signals. 
Results 
Fluorescent Intercalator Displacement Assay 
 To determine if compound inhibition of bacterial RNAP was potentially occurring via non-
specific inhibition by DNA binding, the 15 active compounds identified from the HTS were 
evaluated for displacement of ethidium bromide from a DNA template.  The compounds were 
tested at four different concentrations (12.5 – 100 µM) using the FID assay to determine if the 
compounds potentially inhibit RNA polymerase by binding DNA.  Berenil (diminazine aceturate), 
Figure IV-4.  Fluorescence inhibition of ethidium bromide by compounds that were active in the 
fluorescent intercalator displacement (FID) assay.  For comparison, data for FID inactive compounds 
(257176, 257181, and 23486) within the same cluster as the FID actives are also shown. 
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a known minor groove binder, was used as a control for assay validation.108  Displacement of 
ethidium bromide by compounds was measured after incubation with a 60-bp double-stranded 
DNA probe (FID-lacUV5).  In addition to the positive control (berenil), three of the compounds 
inhibited fluorescence of ethidium bromide in the FID assay at 100 µM (one had some inhibition 
at 50 µM also) using the FID-lacUV5 probe (Figure IV-4). However, these compounds also 
inhibited fluorescence of ethidium bromide when using a scrambled DNA sequence (data not 
shown), indicating that the binding is non-specific.  For this and reasons in the Discussion section 
below, even though these compounds displace ethidium bromide, it seems likely that their 
inhibition of RNAP is not caused by binding to the DNA. 
MICs against virulent M. tuberculosis and Cytotoxicity 
 The 15 compounds identified from the HTS were tested for inhibition of replicating 
(MABA) and non-replicating (LORA) M. tuberculosis.  Of the compounds tested, only four 
compounds exhibited detectable growth inhibition at concentrations lower than 200 μM (Table 
IV-2 and Figure IV-5), with toxicity IC50 values of 50 – 100 µM against Vero cells in the MTS assay. 
 
 
                  Table IV-2.  MICs of compounds active vs M. tuberculosis H37RV 
 
Compound Cluster MTB WT IC50 (μM) 
MIC90 (μM)  
 MABA LORA  
 257181 1 21 94 90  
 22785 5 53 85 81  
 186618 6 28 79 197  
 193157 6 >200 88 183  
 Rifampin   0.01 0.13 0.46  
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Inhibition of RNAP by Pyrazolopyrimidines 
 A set of 30 commercially available analogs of the pyrazolopyrimidines (cluster 6, Appendix 
IV-1, Figure IV-A1) were purchased from ChemDiv (90% purity), and were tested for 
concentration-dependent inhibition against both E. coli and MTB WT RNAP at concentrations up 
to 200 and 100 µM (respectively) using the plasmid-based transcription assay with pMGA12 as 
the plasmid template.  Three compounds (PP-6, PP-16, and PP-22) had IC50 values less than 200 
µM against E. coli RNAP; however, the most potent compound against MTB RNAP only showed 
33% inhibition at 100 µM (PP-22). 
 The original hit compound 186618 and several analogs were synthesized and tested for 
concentration-dependent inhibition of E. coli and MTB RNAP, but were inactive against both 
enzymes (data not shown).  The compound RAR-1-35 (re-synthesis of 186618) was inactive 
Figure IV-5.  Structures of HTS hits active against MTB in culture and pyrazolopyrimidine analogs 
synthesized and tested for inhibition of E. coli and MTB RNAP.  Top: HTS hits with activity against M. 
tuberculosis in LORA and/or MABA.  Middle: Regioisomer and intermediates of HTS hit 186618.  Bottom:  
Analogs of HTS hit 193157. 
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against both E. coli and MTB RNAP.  A potential alternative product (a structural isomer) was also 
prepared and tested for inhibition (RAR-1-54, Figure IV-5, top).  Only a crude product of RAR-1-
54 was obtained, but the crude product was found to be inactive against both E. coli and MTB 
RNAP.  NMR and MS studies of the purchased compound (186618) and synthesized version (RAR-
1-35) agree with one another, suggesting that the correct compound is the primary organic 
compound in solution.  Analogs of 193157 were synthesized and tested for concentration-
dependent inhibition of E. coli and MTB RNAP (Figure IV-5, bottom and Table IV-3). 
 
Table IV-3.  IC50 values (µM) of 193157 
analogs against E. coli WT RNAP 
 
  
 Compound E. coli MTB  
 RAR-1-63 54 >400  
 RAR-1-80 8.2 >400  
 RAR-1-82 12 >400  
 RAR-1-83 310 >400  
 RAR-1-93 320 >400  
 RAR-1-94 >400 >400  
  
Inhibition of RNAP by Sulfonamides 
 A set of analogs of 257178 and 23486 (11 and 10 analogs, respectively) were purchased 
from VitasM and ChemDiv (Figure IV-6 and Appendix IV-1, Figure IV-A2).  The compounds were 
tested for concentration-dependent inhibition against both E. coli and MTB WT RNAP at 
concentrations up to 400 µM using the plasmid-based transcription assay with pMGA12 as the 
plasmid template.  Only one analog of 23486 had an IC50 value ≤ 400 µM (SA-20, IC50 = 400 µM 
against MTB RNAP).  Seven analogs of 257178 had MTB WT RNAP IC50 values < 400 µM, ranging 
from 250 µM to 370 µM (Figure IV-6).  None of the analogs of 257178 had IC50 values < 400 µM 
against E. coli WT RNAP. 
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Cyanopyrimidine Activity without Nitrile 
 Compounds with and without the aromatic nitrile at position R4 were purchased and 
tested for concentration-dependent inhibition of E. coli WT RNAP (Figure IV-7, Table IV-4).  The 
compounds that lacked an aromatic nitrile did not inhibit RNAP at concentrations up to 200 µM, 
while analogous compounds with the nitrile had determinable IC50 values less than 200 µM (Table 
IV-4). 
  
Figure IV-6.  Analogs of HTS hit 257178 tested for inhibition against E. coli and MTB WT RNAPs in the 
plasmid-based transcription assay.  IC50 values listed are against MTB WT RNAP, other compounds did not 
have a determinable IC50 against MTB WT RNAP.  Compounds did not display 50% inhibition against E. coli 
WT RNAP at concentrations up to 400 µM. 
Figure IV-7.  Structure of cyanopyrimidine 
scaffold tested for activity against E. coli and 
MTB WT RNAPs 
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Table IV-4.  Activity of cyanopyrimidines +/- nitrile in 
plasmid-based transcription assay  
Linker (L) = CH2 
R2 = H, R5 = H  IC50, μM 
R1 R3 R4  R6 = CN R6 = H 
H H H 200 >200 
H H Cl 50 (CN-1) >200 (CN-2) 
H Cl H 90 >200 
OCH3 CN H 150 ND 
OCH3 H H 100 (CN-3) ND 
H CN H ND >200 
ND = Not determined 
 
 Reversibility of Cyanopyrimidines 
 A couple representative compounds (CN-1, CN-2, CN-3 – Table IV-4) were tested for 
irreversible inhibition of E. coli WT RNAP by preincubating the compounds with RNAP, followed 
by a 100-fold dilution and transcription initiation.  It was determined that RNAP retained 
transcriptional activity after the 100-fold dilution (Figure IV-8), indicating that the 
cyanopyrimidines are reversible inhibitors of bacterial RNAP. 
 
Figure IV-8.  Plasmid-based transcription assay after RNAP preincubation with compounds.  
RNAP-compound mixtures were diluted 100-fold (from 200 µM compound to 2 µM, 
decreasing [compound] >10-fold below IC50 values), followed by transcription initiation. 
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Nitrile Reactivity Assay 
 The four cyanopyrimidines identified from the HTS were tested for reactivity with L-
cysteine.  None of the cyanopyrimidine compounds showed adduct formation, while the positive 
control 5-bromopyrimidine-2-carbonitrile was 100% converted to an adduct (Figure IV-9 and 
Appendix IV-3) with an m/z of 242 in negative ion mode, indicating an exact mass of 243.  The 5-
bromopyrimidine-2-carbonitrile/L-cysteine adduct had two peaks of similar intensity with m/z 
values of 242 and 244, indicating the presence of the two bromine isotopes, as expected. 
 Inhibition of RNAP by Cyanopyrimidines 
 The compounds 257176 and 257181 identified from the HTS were synthesized and their 
inhibition of E. coli and MTB WT RNAP was confirmed in the plasmid-based transcription assay 
with pMGA12.  A set of 27 cyanopyrimidine analogs (Figure IV-A3) were purchased and tested 
for inhibition against E. coli and MTB WT RNAPs using the plasmid-based transcription assay with 
pMGA4-Ec or pMGA4-Mtb, respectively.  The compounds for this cyanopyrimidine scaffold 
Figure IV-9.  LC-MS chromatogram of positive control (5-bromopyrimidine-2-carbonitrile) and exemplary 
cyanopyrimidine (257176).  The m/z values are from MS detection in negative ion mode. 
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(Figure IV-7) were evaluated for concentration-dependent inhibition up to 400 µM and IC50 values 
were determined for the compounds tested (Table IV-5).  The compounds had IC50 values ranging 
from 5 µM to > 400 µM, indicating the potential for further SAR studies. 
Discussion 
 The top scaffolds of interest identified from a 150,000-compound high-throughput screen 
have been further studied and evaluated for their potential as bacterial RNAP inhibitors.  Initial 
control screens during the HTS triage eliminated scaffolds that inhibited MG fluorescence or were 
not concentration-dependent.  We further evaluated the scaffolds identified to validate their 
inhibition of bacterial RNAP and determine the potential of these scaffolds for future SAR studies.  
Research studying inhibition of DNA binding proteins by small molecules has utilized the FID assay 
to determine if the compounds potentially inhibit the protein by binding to DNA.105  We utilized 
this approach and screened the 15 compounds identified for displacement of the fluorescent 
intercalator ethidium bromide.  Only three of the compounds (257180, 257182, and 19247) 
inhibited fluorescence in the FID assay, which is indicative of DNA binding.  However, this only 
occurred at concentrations more than 10-fold higher than their RNAP IC50s.  Therefore, it is 
reasonable to deduce that these compounds do not exhibit their RNAP inhibitory activities via 
DNA binding. 
 Nine compounds identified from the HTS had similar IC50 values across the panel of RNAP 
enzymes tested (Chapter III, Table III-4); however, only two of these compounds were active 
against M. tuberculosis in culture (257181 and 22785, Table IV-2).  Two compounds from the 
pyrazolopyrimidine scaffold were also active in culture (186618 and 193157).  Interestingly, 
compound 193157 was active in culture despite being inactive against MTB WT RNAP in vitro. 
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Table IV-5.  Structure-activity relationship table of cyanopyrimidines against E. coli and MTB 
WT RNAPs 
Compound Linker 
R1     
(para) 
R2 
(meta) 
R3  
(para) 
R4 
(meta) 
R5 
(ortho) 
IC50 (µM) 
E. coli MTB 
257176 CH2 H H Cl H H 84 130 
257180 CH2 H H H Cl H 55 80 
CN-14 CH2 H H H H Cl 33 66 
CN-12 CH2 H H H H 2,6-Cla 28 38 
CN-25 CH2 H H F H H 47 110 
CN-23 CH2 H H Br H H 31 37 
CN-38 CH2 C(CH3)3 H Br H H 12 4.8 
CN-18 CH2 H H H CONH2 H >400 >400 
CN-34 CH2 Cl H COOH H H >400 >400 
CN-16 CH2 OCH3 H Phenyl H H 33 15 
CN-15 CH2 OCH3 H H H Cl 28 45 
CN-20 CH2 OCH3 H Cl H Cl 24 27 
CN-30 CH2 CH3 H H H H 40 75 
CN-27 CH2 CH3 H CH3 H H 28 38 
CN-22 CH2CH2O H H H H H 50 100 
257181 CH2CH2O Cl H OCH3 H H 37 51 
CN-36 CH2CH2O Cl H Cl H H 18 15 
CN-28 CH2CH2O H H CH3 H H 26 58 
CN-33 CH2CH2O H H OCH3 H H 50 95 
CN-31 CH2CH2O CH3 H CH3 H H 22 31 
CN-26 CH2CH2O CH3 H OCH3 H H 28 50 
CN-35 CH2CH2O Cl H H CH3 H 23 24 
CN-37 (CH2)3O Cl H Cl H H 17 15 
CN-24 (CH2)4O H H CH3 H H 18 20 
257182 (CH2)4O H H Cl H H 36 37 
CN-17 CH2CC OCH3 H Cl H H 23 18 
CN-13 CH2CO CH3 H Cl H H 160 94 
CN-32 CH2COOCH2 Cl H H H H >400 >400 
CN-21 CH2COOCH2CH2O H H H H H 160 290 
CN-29 CH2CONHCH2 Cl H H H H 350 380 
Structures are based on Figure IV-7 where R6 = CN     
a2,6-dichloro with Cl at both ortho positions on phenyl ring attached to linker (L)  
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It is possible that the activity of 193157 against M. tuberculosis is due to off-target or non-specific 
activity.  However, it is known that M. tuberculosis does metabolize a number of drugs to more 
active forms109–112, therefore our compound may be metabolized (e.g., reduction of the nitro) to 
an active, RNAP-inhibiting derivative.  Compound 193157 was synthesized and its activity against 
E. coli WT RNAP was confirmed.  To further evaluate 193157 and the potential cellular 
metabolism of it, a set of analogs to 193157 were synthesized (Figure IV-5, bottom).  The methyl 
and chloro substituents on the para position were more active than the fluoro; however, both 
were still inactive against MTB RNAP (Table IV-3).  To evaluate the possibility that reduction of 
the nitro yields an active species against MTB WT RNAP, compounds with an amine (RAR-1-94) 
or without the nitro group (RAR-1-93) were synthesized (Figure IV-5, bottom) and evaluated for 
inhibition of E. coli and MTB WT RNAPs.  The compound with the amine was inactive, and the 
compound without the nitro was weakly active against E. coli WT RNAP (Table IV-3).  Since the 
amine was inactive, and all the analogs tested had IC50 values near or > 400 µM, analogs of 
193157 were not pursued further. 
Compound 186618 was active against all RNAP enzymes tested, and active against 
replicating and non-replicating M. tuberculosis.  This compound was synthesized, the structure 
and purity were confirmed (Rachel Rowlands and Dr. Andy White), and found to exhibit very low 
activity similar to other cluster 6 analogs.  The NMR spectra and mass matched with the 
purchased compound and what was expected for the structure.  Unfortunately, there was only a 
small amount of the purchased 186618 and it was no longer available from ChemDiv or other 
vendors, so we were unable to perform further analyses to determine the potential active 
component.  The synthetic intermediates RAR-1-37 and RAR-1-52 were characterized and tested 
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for activity against E. coli and MTB RNAPs, with RAR-1-37 having an IC50 near 200 µM (Table IV-
3).  The regioisomer RAR-1-54 was synthesized and did not inhibit E. coli or MTB RNAP at 
concentrations up to 200 µM.  Based on these results, we suspect that the activity of the 
purchased sample of 186618 was due to a contaminant that we were unable to identify. 
 A set of sulfonamide analogs with structural similarity to 257178 or 23486 were evaluated 
for inhibition of E. coli and MTB WT RNAPs.  Analogs of 257178 were all weakly active with IC50 
values of 300 µM or greater.  The diversity of the commercially available analogs of 257178 is 
quite limited, mainly consisting of variations on the phenyl ring attached to the sulfonyl group.  
Additionally, 257178 is a charged molecule in aqueous solutions at physiological pH, with the 
negative carboxyl group on the phenyl ring.  It is possible that this carboxyl group is important 
for binding, while the analogs tested do not contain the carboxyl group.  A couple analogs have 
oxygen atoms that could act as a hydrogen bond donor (SA-5, SA-9), but do not have the potential 
for the same negative electrostatic interactions as a carboxyl group.  This compound (or any 
analogs) was not synthesized to reconfirm and evaluate the activity due to the synthetic difficulty 
of this molecule compared to other scaffolds of interest.  All the analogs of 23486 tested had IC50 
values ≥ 400 µM (Figure IV-A2), indicating that the scaffold is not optimal for an SAR campaign. 
 Initially, the cyanopyrimidine scaffold was of low interest due to the reported potential 
of these compounds for pan-assay interference via covalent interaction with cysteines.100  
However, over 30 nitrile-containing compounds are in clinical use, with additional lead 
compounds in clinical development.113  The largest class of nitrile-containing drugs are 
compounds with an aromatic core containing a nitrile substituent, as is the case for the 
cyanopyrimidine scaffold identified from the HTS.  These nitriles often act as hydrogen bond 
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acceptors with their therapeutic target; however, only a few have been shown to act 
covalently.114  Given that numerous drugs containing aromatic nitriles are in clinical use, the mere 
presence of the aromatic nitrile should not block further development.  Therefore, these nitrile 
containing compounds were subjected to additional investigation. 
Testing a series of analogs that contained or lacked the aromatic nitrile (Table IV-4) 
revealed that analogs without the nitrile were essentially inactive.  This result agreed with our 
original hypothesis, that the cyanopyrimidine compounds could potentially be inhibiting bacterial 
RNAP non-specifically by covalently interacting with cysteine.  However, it is also possible that 
removing a potential hydrogen bond acceptor (nitrile) would decrease the activity of an inhibitor, 
so this result by itself did not determine if the cyanopyrimidines act via covalent inhibition.  In 
order to confirm or refute this hypothesis, further testing was still necessary. 
 First, it was determined whether the compounds irreversibly inhibited E. coli WT RNAP by 
incubating the compounds with RNAP followed by dilution to reduce the concentration of 
compound significantly below the IC50.  Therefore, if the compound reversibly inhibits RNAP, the 
compound would be able to dissociate from RNAP and transcription would occur.  As seen in 
Figure IV-8, RNAP that was preincubated with the active compounds CN-1 and CN-3 (IC50s = 50 
and 100 µM, Table IV-4), then diluted 100-fold retained activity.  The inactive compound CN-2 
(lacking aromatic nitrile) was tested as a control, showing that the RNAP is active in the presence 
of CN-2 and that preincubation and dilution did not affect the enzyme.  The results from these 
experiments show that the cyanopyrimidine compounds reversibly inhibit bacterial (E. coli) 
RNAP.  However, these results do not refute the possibility that the aromatic nitrile might 
covalently interact with an off-target enzymatic cysteine resulting in toxicity. 
78 
 
The cyanopyrimidine compounds identified from the HTS (257176, 257180, 257181, and 
257182) were tested for adduct formation with L-cysteine.  This assay was utilized to determine 
the potential of the compounds to non-specifically, covalently interact with cysteine.  It has been 
shown that depending on the electrophilicity of the aromatic nitrile, nitriles similar to the 
cyanopyrimidines can form cysteine adducts in solution with L-cysteine.100  As shown in Figure 
IV-9 and Appendix IV-3, the compounds tested did not form cysteine adducts, indicating that the 
compounds are not electrophilic enough to interact with cysteines.  The positive control used for 
this assay, 5-bromopyrimidine-2-carbonitrile, formed an adduct with an m/z of 242 in negative 
ion mode, indicating an exact mass of 243.  The expected exact mass of the adduct that would 
form based on the proposed reaction in Figure IV-10 is 287.  It is possible that the carboxylate 
from the cysteine was lost in the form of CO2 (MW = 44) to give an adduct with a mass of 243. 
Based on the data obtained for this cyanopyrimidine scaffold, these compounds are likely 
specific inhibitors of bacterial RNAP.  The compounds inhibit both WT and RifR RNAPs for E. coli 
and MTB (Chapter III, Table III-4), therefore it is likely that they do not bind in the rifamycin 
Figure IV-10.  Proposed reaction for nitrile reactivity assay.  Top: Reaction for generic 
nitrile with L-cysteine.  Bottom:  Proposed adduct formed and detected in 
electrospray ionization (negative mode). 
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binding pocket.  For future analogs of this scaffold, it is important to keep in mind the potential 
for them to be PAINS.  If the core pyrimidine ring is changed where the electrophilicity of the 
nitrile may increase, such analogs should be tested in the nitrile reactivity assay.  Iterative design, 
synthesis and testing is necessary to find more potent inhibitors of WT and RifR MTB RNAP. 
Conclusions 
 The top scaffolds of interest identified from a high-throughput screen (Chapter III) were 
evaluated for their potential as a bacterial RNAP inhibitor.  The pyrazolopyrimidine scaffold 
(Cluster 6) was eliminated because the most promising compound (186618) was not confirmed 
after synthesis, and an initial SAR effort with commercially available analogs did not identify 
additional active compounds.  The sulfonamides (Clusters 2 and 3) were also eliminated because 
the initial SAR effort with commercially available analogs did not identify additional active 
compounds. 
Based on initial experiments, the cyanopyrimidines (Cluster 1) require the nitrile group 
for activity; however, it was determined that they do not irreversibly inhibit E. coli RNAP in vitro.  
Furthermore, it was determined that the cyanopyrimidines do not form adducts with L-cysteine 
in the nitrile reactivity assay, further indicating that their mechanism of inhibition is not via non-
specific interactions with a cysteine on bacterial RNAP.  Based on these results and the initial SAR 
from commercially available analogs, this scaffold merits further study as a bacterial RNAP 
inhibitor. 
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Appendix IV-1 
Purchased Analogs of Scaffolds Identified from HTS 
 A set of commercially available analogs were purchased for each scaffold of interest 
identified from the HTS.  A set of 30 analogs of 186618 (pyrazolopyrimidine, cluster 6, Figure IV-
A1) were purchased from ChemDiv and tested against E. coli and MTB WT RNAPs in the plasmid-
based transcription assay using pMGA12.  The IC50 values in Figure IV-A1 are against E. coli WT 
RNAP.  None of the compounds reached 50% inhibition at the highest concentration tested 
against MTB WT RNAP (100 µM). 
 A set of analogs of 257178 (Figure IV-6) and 23486 (Figure IV-A2) were purchased from 
ChemDiv (90% purity) and VitasM (92% purity).  Each analog was tested against E. coli and MTB 
WT RNAPs in the plasmid-based transcription assay using pMGA12.  The IC50 values in Figure IV-
A1 are against MTB WT RNAP.  None of the compounds reached 50% inhibition at the highest 
concentration tested against E. coli WT RNAP (400 µM). 
 A set of 27 analogs for the cyanopyrimidine scaffold (Figure IV-A3) were purchased from 
various suppliers and tested for inhibition of E. coli and MTB WT RNAPs in the plasmid-based 
transcription assay using pMGA4-Ec or pMGA4-Mtb, respectively.  The IC50 values for the 
compounds ranged from 5 µM to > 400 µM against E. coli and MTB WT RNAPs. 
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Figure IV-A1.  Pyrazolopyrimidine analogs tested for inhibition against E. coli and MTB WT RNAPs in the 
plasmid-based transcription assay.  IC50 values listed are against E. coli WT RNAP, other compounds did 
not have a determinable IC50 against E. coli WT RNAP.  Compounds did not display 50% inhibition against 
MTB WT RNAP at concentrations up to 100 µM. 
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Figure IV-A2.  Analogs of 23486 tested for inhibition against E. coli and MTB WT RNAPs in plasmid-based 
transcription assay.  IC50 value listed is against MTB WT RNAP, other compounds did not have a 
determinable IC50 against MTB WT RNAP.  Compounds did not display 50% inhibition against E. coli WT 
RNAP at concentrations up to 400 µM. 
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Figure IV-A3.  Analogs of cyanopyrimidine scaffold tested for inhibition against E. coli and MTB WT RNAPs 
in plasmid-based transcription assay. 
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Appendix IV-2 
Chemistry and Synthesis 
 Compounds were synthesized by Rachel Rowlands using the reaction schemes in Figures 
IV-A4 and IV-A5 for the 186618 and 193157 pyrazolopyrimidine analogs and intermediates, and 
Figure IV-A6 for the cyanopyrimidine compounds. 
1H NMR spectra were recorded on Bruker 500 MHz spectrometers.  Chemical shifts are 
reported in δ (parts per million, ppm), by reference to the hydrogen residues of deuterated 
solvent as internal standard (CDCl3: δ = 7.28 ppm; DMSO-d6: δ = 2.50 ppm).  Signals are described 
as s, d, t, q, m, dd, dt, ddt for singlet, doublet, triplet, quartet, multiplet, doublet of doublets, 
doublet of triplets, and doublet of doublet of triplets, respectively.  Coupling constants (J) are 
given in Hertz (Hz). 
 
 
Figure IV-A4.  Synthetic scheme for RAR-1-35, RAR-1-54, and intermediates. 
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RAR-1-35 (186618) 
MS: m/z 372.  1H NMR (500 MHz, CDCl3): δ 1.16 (s, 3H), 2.55 (s, 7H), 3.86 (s, 3H), 3.94 (s, 3H), 6.78 
(s, 1H), 7.42 (d, 2H), 7.49 (s, 1H), 7.51 (d, 2H). 
RAR-1-37 
1H NMR (500 MHz, CDCl3): δ 7.84 (s, 1H), 7.54 (d, 2H), 7.52 (s, 1H), 7.43 (d, 2H), 4.12 (s, 3H). 
Figure IV-A6.  Synthetic scheme for cyanopyrimidines 257176 and 257181. 
Figure IV-A5.  Synthetic scheme for 193157 analogs and intermediates. 
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RAR-1-52 
1H NMR (500 MHz, DMSO-d6): δ 8.4 (s, 1H), 3.8 (s, 3H), 3.6 (m, 2H), 3.1 (m, 4H), 1.3 (m, 4H), 1.2 
(m, 3H).  
RAR-1-54 
MS: m/z 352.  1H NMR (500 MHz, DMSO-d6): δ 8.38 (s, 1H), 7.06 (d, 3H), 6.96 (d, 4H), 3.92 (s, 3H), 
1.23 (m, 11H), 1.08 (m, 7H), 0.88 (m, 10H). 
RAR-1-63 (193157) 
1H NMR (500 MHz, CDCl3): δ 9.28 (s, 1H), 8.338 (s, 1H), 7.33 (t, 2H), 7.19 (t, 2H), 6.98 (s, 1H), 
6.42 (s, 1H), 2.46 (s, 3H).  19F NMR (500 MHz, CDCl3): -120. 
RAR-1-80 
1H NMR (400 MHz, CDCl3): δ 9.26 (s, 1H), 8.30 (s, 1H), 7.24 (d, 2H), 7.16 (d, 2H), 7.04 (s, 1H), 6.48 
(s, 1H), 2.43 (s, 3H), 2.39 (s, 3H). 
RAR-1-82 
1H NMR (500 MHz, CDCl3): δ 9.28 (s, 1H), 8.34 (s, 1H), 7.45 (d, 2H), 7.33 (d, 2H), 7.06 (s, 1H), 6.53 
(s, 1H), 2.51 (s, 3H). 
RAR-1-83 
1H NMR (500 MHz, CDCl3): δ 9.32 (s, 1H), 8.31 (s, 1H), 7.85 (s, 1H), 7.50 (m, 2H), 7.28 (m, 3H), 6.62 
(s, 1H), 2.46 (s, 3H) 
RAR-1-93 
MS: m/z 270.  1H NMR (500 MHz, CDCl3): δ 8.58 (d, 1H), 7.82 (s, 1H), 7.32 (q, 2H), 7.16 (t, 2H), 
6.94 (s, 1H), 6.48 (s, 1H), 6.34 (s, 1H), 2.45 (s, 3H).  19F NMR (500 MHz, CDCl3): δ -120. 
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RAR-1-94 
MS: m/z 281.  1H NMR (500 MHz, CDCl3): δ 8.10 (s, 1H), 7.64 (s, 1H), 7.50 (s, 1H), 7.32 (m, 1H), 
7.16 (m, 1H), 7.10 (s, 1H), 7.04 (d, 1H), 6.45 (s, 1H), 2.43 (s, 6H, incidental Me overlap)  
13C NMR (500 MHz, CDCl3): δ 168.10, 162.43, 155.51, 129.54, 137.97, 136.00, 129.97, 125.98, 
123.61, 119.99, 115.42, 98.98, 24.30, 21.42 
257176 
MS: m/z 354.  1H NMR (500 MHz, DMSO-d6): δ 7.93 – 7.88 (m, 2H), 7.63 (t, J = 7.3 Hz, 1H), 7.58 
(dd, J = 8.2, 6.4 Hz, 2H), 7.51 (d, J = 1.9 Hz, 1H), 7.39 (dt, J = 7.2, 1.8 Hz, 1H), 7.36 – 7.30 (m, 2H), 
4.52 (s, 2H). 
257181 
MS: m/z 354.  1H NMR (500 MHz, CDCl3): δ 7.89 (dt, J = 12.5, 7.9 Hz, 2H), 7.58 (ddt, J = 16.8, 12.5, 
7.3 Hz, 3H), 7.49 – 7.29 (m, 4H), 4.55 – 4.46 (m, 2H). 
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Appendix IV-3 
Nitrile Reactivity Assay 
 The positive and negative controls 5-bromopyrimidine-2-carbonitrile and CCG-257084, 
respectively, were used for assessing nitrile reactivity for this assay based on data previously 
reported.100  Four cyanopyrimidines identified from the HTS were tested for reactivity with L-
cysteine in this aqueous assay.  The reactions were applied to a pre-equilibrated Shimadzu LC-
MS.  The samples were separated and eluted using a 10% to 90% acetonitrile in water gradient 
over the course of 15 min.  The chromatograms reported in Figure IV-A4 are the Absorbance 
intensity as a function of time in minutes.  The UV absorption is measured using a photodiode 
array at a wavelength of 254 nm. 
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Figure IV-A7.  LC-MS chromatogram of negative control CCG-257084 and cyanopyrimidines 257180, 
257181, and 257182.  The m/z values are from MS detection in negative ion mode. 
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Chapter V 
In vitro Evaluation of Benzoxazinorifamycin Analogs against Wild-type and Rifamycin-
Resistant Mutants of Escherichia coli and Mycobacterium tuberculosis RNA Polymerase 
 There have been few improvements in the treatment success and global burden of 
multidrug-resistant TB (MDR-TB) over the past decade.  Each year, there are approximately half 
a million new cases reported.2  Cases of MDR-TB are resistant to the two first-line drugs used 
throughout treatment, rifampin and isoniazid.  Due to the resistance of M. tuberculosis to these 
drugs, MDR-TB treatment consists of second-line injectable anti-TB drugs such as 
fluoroquinolones and aminoglycosides.115,116  In addition to the cost and issues related to 
intravenous administration of drugs, the length of therapy is 9 to 12 months (previously 18 to 24 
months) instead of a 6-month treatment for drug-susceptible TB.2  It is therefore of interest to 
identify agents that are able to overcome the issues of drug-resistant TB. 
 Rifampin-resistant (RifR) TB is primarily caused by single amino acid mutations in a portion 
of the rpoB gene that encodes the β subunit of RNAP where rifampin binds.  Rifamycins inhibit 
RNAP transcription initiation by preventing the formation of nascent RNA longer than 2 or 3 
nucleotides, but they do not inhibit RNA transcription in the elongation phase.117  The three most 
prevalent amino acid mutations are D516V, H526Y, and S531L (E. coli numbering).  Rifampin and 
several other rifamycins have been tested in vitro against RNAP with these clinically relevant 
mutations, and it was shown that the RifR mutants are approximately 104 to 105-fold less 
susceptible to rifampin.56  However, this work also demonstrated that the rifamycin analog 
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rifabutin was 10- to 50-fold more potent than rifampin against D516V and S531L E. coli RNAP.  
Therefore, it appears that additional improvements to the activity against RifR mutants can be 
achieved through improved design of rifamycin analogs. 
 In addition to the issues of rifamycin resistance, rifampin is also a potent inducer of 
CYP3A4 by activating the human pregnane X receptor (hPXR).47  Rifalazil, a benzoxazinorifamycin 
(bxRif) analog developed and tested in phase I and II clinical trials, was of great interest for several 
reasons.  It is an exceedingly potent rifamycin with high tissue affinity, a longer half-life than 
rifampin, and had a relative lack of toxicity in early rodent studies.46,48,52  Additionally, rifalazil did 
not show induction of CYPs or activation of hPXR as is seen for rifampin.49,57  Unfortunately, 
rifalazil was shown to be toxic in phase I and phase II clinical trials with a flu-like syndrome and 
Figure V-1.  Structures of benzoxazinorifamycins and the clinical rifamycins rifampin and rifabutin. 
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leucopenia, even at lower dosage levels.52,118,119  Therefore, its development for the treatment 
of TB was suspended.44  Aside from the toxicity issues of rifalazil, it demonstrated that a more 
potent rifamycin analog without the issues of drug-drug interactions can be developed. 
 Rifalazil and the bxRifs are a newer generation of rifamycin derivatives with a four-ring 
structure (Figure V-1).  The bxRifs have shown improved antimicrobial activity against M. 
tuberculosis (MTB) and in vitro activity against RifR RNAPs.48,57,120  Prior work with the bxRifs 
resulted in the development of bxRif analogs 2b – 2d using modeling based on the 2.5 Å 
resolution structure of rifabutin (Figure V-1) in complex with the Thermus thermophilus RNAP 
holoenzyme (Figure V-2, PDB: 2A68).57  These analogs were developed with the goal of 
interacting with the σ hairpin loop and other portions of the RNAP complex.  The bxRif analogs 
prepared showed improved activity in vitro; however, the structure-based design utilized the 
Thermus thermophilus structure.  The sequence and antibiotic sensitivities of the E. coli RNAP are 
closer to those of the MTB RNAP than are those of T. thermophilus RNAP, i.e., the E. coli RNAP is 
a better model to study RNAP – inhibitor interactions for TB drug discovery.117  Recent work on 
bacterial RNAP has resulted in the structural determination of E. coli RNAP holoenzyme (PDB: 
Figure V-2.  Rifabutin bound to Thermus thermophilus RNAP (PDB: 2A68).  RNAP molecular surface is 
shown with β subunit colored grey, β’ in gold, and sigma factor in red. 
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4YG2).95  Therefore, the structure of rifampin and bxRif analogs in complex with E. coli WT RNAP 
holoenzyme was determined to evaluate their binding and interactions, and correlate the in vitro 
activities to the structural data.96   
 To further understand the binding of rifamycins to RifR RNAP and the effects of these RifR 
mutations (D516V, H526Y, S531L – E. coli numbering), we evaluated the rifampin inhibition of 
these mutants for E. coli and MTB RNAPs as well as recent X-ray crystal structures of E. coli RifR 
RNAPs in complex with rifampin in collaboration with the Murakami lab (Penn State University).  
With the goal of identifying a potent rifamycin analog against MTB in culture as well as WT and 
RifR RNAP, we developed and tested a series of novel bxRif analogs for their in vitro and cellular 
activity. 
Materials and Methods 
Materials 
 All the materials were the same as those specified in Chapter II.  Oligonucleotides used in 
this study were purchased from Invitrogen (Table V-1).  Quant-iT RiboGreen was purchased from 
ThermoFisher (Waltham, MA).  Reagents used for rolling circle transcription assay were 
purchased from Epicentre (Madison, WI).  The transcription plasmid templates were purified as 
described for pMGA12 in Chapter III.  The crystallography work was done by Drs. Katsu Murakami 
and Vadim Molodtsov.  Synthesis of bxRifs was done by Dr. Walajapet Rajeswaran based on 
methods previously published.57  DNA sequencing was performed by the University of Michigan 
Biomedical Resources Core Facility. 
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Purification of E. coli and MTB RNAPs 
 For expression of the E. coli RNAP, a plasmid containing E. coli σ70 (without His tag) that 
was compatible with the pVS10 expression vectors (for co-expression) was prepared using the 
pRSFDuet-1 vector, pET15b-Sig70, and the oligonucleotides listed in Table V-1.  One of the T7 
promoters on the co-expression plasmid pRSFDuet-1 was removed via two-step site-directed 
mutagenesis using the complementary oligonucleotides pRSF-T7Del-Fwd and pRSF-T7Del-Rev to 
give pRSF-1.  The plasmid was verified by DNA sequencing.  An NdeI restriction site in the E. coli 
rpoD gene (Sig70) was mutated (silent mutation to preserve protein sequence) using site-
directed mutagenesis with the complementary oligonucleotides EcSig70-NdeIMut-Fwd and 
EcSig70-NdeIMut-Rev.  The resulting plasmid and pRSF-1 were digested with NdeI and EcoRV, 
then gel purified.  The E. coli rpoD fragment and vector pRSF-1 were ligated to give the expression 
plasmid pRSF-Sig70.  Plasmid was verified by DNA sequencing. 
E. coli RNAP holoenzymes (WT, D516V, H526Y, S531L, βS531L/β’V408G) were expressed 
and cells harvested as described in Chapter II, with cells containing expression vectors pVS10 and 
pRSF-Sig70 grown and expressed in terrific broth with 1 mM ZnCl2 instead of 2xTY.  MTB RNAP 
holoenzymes (WT, D435V, H445Y, S450L, βS450L/β’V483G) were expressed and cells harvested 
as described in Chapter II, with cells grown and expressed in terrific broth with 1 mM ZnCl2 
instead of 2xTY. 
Table V-1.  List of oligonucleotides used  
Oligonucleotide Name Sequence, 5' - 3' Length 
pRSF-T7Del-Fwd GCGACTCCTGCATTAGGCAGGTCGACAAGCTTGC 34 
pRSF-T7Del-Rev GCAAGCTTGTCGACCTGCCTAATGCAGGAGTCGC 34 
EcSig70-NdeIMut-Fwd CCGTATTCCGGTGCACATGATTGAGACCATCAACAAG 37 
EcSig70-NdeIMut-Rev CTTGTTGATGGTCTCAATCATGTGCACCGGAATACGG 37 
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E. coli RNAPs were purified as follows.  Cell pellet from 1 L of culture was resuspended in 
20 mL of RNAP lysis buffer (20 mM Tris-HCl (pH 8.0), 200 mM NaCl, 20 µM ZnCl2, 5% glycerol, 2 
mM β-mercaptoethanol, 1 mM PMSF and 1X Roche cOmplete ULTRA protease cocktail).  Cells 
were lysed by sonication and clarified by centrifugation at 25,000 x g for 45 min.  RNAP was 
precipitated by addition of 10% polymine P (pH 7.9) to a final concentration of 0.6% polymine P, 
followed by centrifugation at 6,000 x g for 10 min.  The pellet was washed by resuspension in 12 
mL RNAP lysis buffer containing 500 mM NaCl, followed by centrifugation (6,000 x g, 10 min. 4°C).  
RNAP was then solubilized with 20 mL RNAP lysis buffer containing 1 M NaCl, and clarified by 
centrifugation (8,000 x g, 10 min, 4°C).  RNAP was precipitated from the supernatant by addition 
of 0.3 g ammonium sulfate per mL supernatant (6 grams), followed by incubation at 4°C for 30 
min. After centrifugation (10,000 x g, 30 min, 4°C), RNAP was resuspended in ~5 mL dialysis buffer 
and dialyzed overnight (20 mM Tris-HCl (pH 8.0), 75 mM NaCl, 20 µM ZnCl2, 5% glycerol, 2 mM β-
mercaptoethanol). Dialyzed RNAP was sterile filtered and applied to a 1-mL HisTrap HP column 
(GE Healthcare) and purified by FPLC (ÄKTA, GE Healthcare). Isolated holoenzyme was then 
further purified on a 5-mL Source 15S column (cation exchange), followed by a 5-mL Source 15Q 
column (anion exchange). 
MTB RNAPs were purified in the same manner as E. coli RNAPs with the following 
modifications.  After ammonium sulfate precipitation and dialysis, MTB RNAP was applied to the 
5-mL Source 15S column, followed by the 1-mL HisTrap column, then the 5-mL Source 15Q 
column.  Purified MTB RNAP fractions were collected, dialyzed into storage buffer (40 mM Tris-
HCl (pH 7.9), 200 mM NaCl, 0.1 mM EDTA, 1 mM MgCl2, 20 µM ZnCl2, 50% glycerol, and 5 mM 
DTT), and stored at -20°C.  E. coli σ70 and MTB SigA were purified as described in Chapter III. 
97 
 
Rolling Circle Transcription Assay (RiboGreen Detection) 
The activity of E. coli WT and RifR RNAPs were measured via rolling circle transcription 
assay using the Kool NC-45 Universal RNA Polymerase template in the absence and presence of 
bxRifs.  Concentration-response studies with rifalazil (bxRIF2a) and bxRif analogs (bxRif2b−d) 
were performed via rolling circle transcription assay in the same manner as previously described 
to determine IC50 values against E. coli RNAPs.  In brief, core E. coli RNAP (10 nM for WT, 100 nM 
for mutants) was incubated with the test compound for 10 min at 37 °C in a 25 μL reaction volume 
of 1× RNAP reaction buffer (40 mM Tris-HCl (pH 8.0), 50 mM KCl, 10 mM MgCl2, 0.01% Triton X- 
100), 8 mM DTT, and 1.12 U/μL RNase inhibitor. The DNA nanocircle template (NC-45, 80 nM) 
was added next, followed by reaction initiation with 500 µM NTP solution (each NTP = 500 µM).  
Aliquots of 2 µL were taken every 30 min for 2 hr starting at t = 0 min and quenched in 75 µL TE 
buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5).  Amount of RNA synthesized was measured by the 
addition of 75 µL of 1:200 diluted RiboGreen in TE buffer, followed by fluorescence measurement 
using a Synergy H1 Hybrid plate reader with excitation and emission wavelengths of 480 nm and 
520 nm, respectively.  Each of the compounds was tested in duplicate (n = 2) at eight different 
concentrations. 
An RNA standard curve was made using varying concentrations of tRNA, and the curve 
was used to convert the fluorescence values to the concentration of RNA at each time point.  
Data were analyzed and IC50 values were determined as described in Chapter II, normalizing rate 
of RNA synthesis to percent activity and fitting data by nonlinear regression. 
Plasmid-Based Time Course Transcription Assay with Heparin 
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 Time course transcription assays were prepared as described in Chapter III with the 
following modifications.  The 2x E. coli reaction buffer and 2x MTB reaction buffer solutions did 
not contain NTPs and contained either pMGA12, pMGA4-Ec, or pMGA4-Mtb.  The 2x reaction 
buffer (72 µL) was incubated with 75 µL of 2x RNAP solution for 20 min.  Before initiation with 3 
µL of 25 mM NTPs, 1.5 µL of 5 mg/mL heparin or 1.5 µL of H2O was added to reactions in triplicate.  
Aliquots of 10 µL were removed from the reaction mixture every 30 min.  Before taking the 30-
min time point, 1.3 µL of 5 mg/mL Heparin was added to a set of reactions (in triplicate) that did 
not contain heparin already.  Fluorescence was measured as described in Chapter III.  Heparin 
was added to the reactions to trap RNAP in an inactive state as depicted in Figure V-3. 
Plasmid-Based Transcription Assay 
 Plasmid-based transcription assays were conducted as described in Chapter IV using 
pMGA4-Ec or pMGA4-Mtb (unless otherwise specified) for E. coli and MTB RNAPs, respectively.  
Compounds were tested in duplicate against WT RNAPs at concentrations of 0.78 – 400 nM with 
an RNAP concentration of 5 nM (σ70/SigA = 15 nM for E. coli/MTB, respectively).  Compounds 
were tested in duplicate against RifR RNAPs (D516V and S531L – E. coli numbering) at 
concentrations of 0.24 – 1000 µM (0.24 – 2000 µM for rifampin).  Rifampin was tested in 
Figure V-3.  Schematic of heparin trapping RNAP in an inactive state.  1) Binding of double-stranded DNA 
(dsDNA) template by RNA polymerase (RNAP) holoenzyme.  2)  Synthesis of RNA transcript by RNAP.  3) 
Binding of Heparin to RNAP that is not bound to dsDNA template.  Heparin-bound RNAP is unable to bind 
dsDNA template and synthesize RNA. 
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triplicate.  Data were analyzed and IC50 values were determined as described in Chapter II, 
normalizing fluorescence values to percent activity and fitting data by nonlinear regression. 
E. coli and MTB RNAPs were tested with and without 200 nM rifampin to evaluate 
endogenous E. coli WT RNAP contamination from the preparation (Appendix V-1). 
Results 
Effect of Rifalazil and bxRifs 2b – 2d on E. coli RNAPs 
 The IC50 values were determined for rifalazil and bxRifs 2b – 2d against E. coli WT, D516V, 
H526Y, and S531L in rolling circle transcription (RiboGreen detection) using core RNAP (Table V-
2).  The IC50 values for bxRifs against E. coli H526Y RNAP were the highest, with all the values 
>1000 µM except for rifalazil.  The bxRifs 2b – 2d all had IC50 values < 100 µM against E. coli D516V 
and S531L RNAP. 
Table V-2.  In vitro IC50 values (µM) for rifampin, rifalazil, and bxRifs b-d in rolling 
circle transcription assay 
RNAP Rifampin Rifalazil bxRIF2b bxRIF2c bxRIF2d 
E. coli WT 0.012 b <0.01 0.057 0.024 0.021 
E. coli D516V 233 b 204 35 2 41 
E. coli H526Y 1130 b 299 1148 ≥ 2000a 1581 
E. coli S531L 171 b 63 64 92 13 
Data for MTB RNAPs 
MTB WT 0.017 b <0.01 c <0.01 c <0.01 c <0.01 c 
MTB D435V 465 b 541 c 20 c 9 c 13 c 
MTB H445Y 610 b 172 c 171 c 437 c 574 c 
MTB S450L 109 b 117 c 16 c 18 c 122 c 
a50% inhibition of transcription was observed at 2000 µM inhibitor 
bFrom Gill, et al. (2011) Tuberculosis 91, 361-369. 
cFrom Gill, et al. (2012) Journal of Medicinal Chemistry 55(8), 3814-3826. 
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X-ray crystal structures were solved for E. coli WT RNAP in complex with either rifampin, 
bxRif2b, or bxRif2c (Appendix V-2).  The structure of E. coli RNAP with bxRif shows interaction of 
bxRif C3’-tail with β fork loop 2 and the σ finger of σ70 (Figure V-4). 
Detection of RNAP Inhibition by Rifampin in Plasmid-Based Transcription Assay 
 Concentration-response studies were done for rifampin against E. coli and MTB RNAPs 
(WT and RifR) using the plasmid-based transcription assay with pMGA12 or pMGA4-Ec and 
pMGA4-Mtb, respectively.  We were unable to determine any IC50 values using pMGA12 for E. 
coli RifR RNAPs (D516V, H526Y, and S531L); however, IC50 values could be determined using the 
plasmid template pMGA4-Ec (Figure V-5, left).  An IC50 value could be determined for MTB RifR 
RNAPs using either pMGA12 or pMGA4-Ec, and the concentration-response curves using the two 
plasmids agreed with one another very well (Figure V-5, right).  IC50 values for rifampin were 
determined against E. coli and MTB RNAPs (WT and RifR, Table V-3) using plasmids pMGA4-Ec 
and pMGA4-Mtb, respectively.  The E. coli RNAP IC50 values correlate well with the MTB RNAPs, 
with E. coli H526Y and MTB H445Y RNAPs being the most resistant to rifampin. 
Figure V-4.  X-ray crystal structure of bxRif2c bound to E. coli RNA polymerase.  The structure indicates 
that the C3’-tail of bxRif2c interacts with both the RNA polymerase and the σ factor. 
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Table V-3.  RNAP IC50 values (µM) for rifampin in plasmid-based transcription assay 
E. coli RNAPs WT D516V H526Y S531L 
Rifampin < 0.005 400 (±120)a ≥ 2000b 260 (±30)a 
MTB RNAPs WT D435V H445Y S450L 
Rifampin < 0.005 880 (±170)a NDIc 790 (±250)a 
aThe errors are standard deviation. All experiments were conducted in triplicate. 
b ~50% inhibition at 2 mM, but an IC50 was not able to be confidently determined. 
cNDI = no detectable inhibition at 2 mM 
 
Effect of Heparin on Plasmid-Based Transcription 
 The activity of E. coli and MTB WT RNAPs were monitored in the presence and absence 
of the negatively charged heparin since it effectively binds and traps RNAP in an inactive state 
(Figure V-3).121  The RNAP activity when using the plasmid templates pMGA12 or pMGA4-Ec was 
monitored over the course of 2 to 3 hours, adding heparin at t = 0 min or t = 30 min (Figure V-6).  
When using the plasmid template pMGA12, which does not contain any terminator sequences, 
there is a minimal effect of heparin on the fluorescence detection of transcription for the first 90 
min of the reaction (Figure V-6, top left).  This indicates that there are very few termination 
Figure V-5.  Concentration-response curves of rifampin against E. coli and MTB RifR RNAP using 
the plasmid-based transcription assay.  Plasmid DNA templates used were either pMGA12, 
pMGA4-Ec, or pMGA4-Mtb with concentration of RNAP and σ70/SigA of 40 and 120 nM, 
respectively. 
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events where RNAP dissociates from the plasmid DNA template, which would allow heparin to 
bind DNA and halt transcription.  On the other hand, when using pMGA4-Ec, transcription ceases 
essentially immediately after addition of heparin (Figure V-6, top right). 
 A similar observation was seen for MTB RNAP.  Heparin has minimal effect on MTB WT 
RNAP transcription from pMGA12 over the course of the assay (3 hrs).  However, the inhibition 
of transcription by heparin is delayed when MTB RNAP is transcribing from pMGA4-Mtb 
compared to E. coli RNAP transcribing from pMGA4-Ec.  It takes approximately 30 min before 
there is a noticeable reduction in transcription by heparin.  This indicates that termination is not 
as efficient for MTB RNAP with this promoter, or MTB RNAP is much slower at transcribing from 
the template – as indicated with the low fluorescence values. 
Figure V-6.  Time course plasmid-based transcription assay of E. coli and MTB WT RNAP with and without 
heparin.  Transcription assays with 40 nM RNAP and 120 nM σ70 or SigA.  Hep = Heparin, rfu = relative 
fluorescence units. 
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Effect of RifR Mutations on E. coli RNAPs 
 In the WT RNAP•RMP complex, the S531 residue forms a hydrogen bond with a phenol 
of the rifampin naphthalene ring (Figure V-7), and the top of the naphthalene ring is covered by 
β subunit loops, including fork loop 2 (residues 534-541, Figure V-8, A – left).  In the crystal 
structure of S531L RNAP-rifampin complex; however, a major difference is observed around the 
β subunit fork loop 2 of which the electron density is weak and scattered compared to its 
counterpart in the WT RNAP•RMP complex (Figure V-A2).  This results in about half of the 
rifampin naphthalene ring being exposed to solvent (Figure V-8, A – right), reducing 
approximately 40% of the contact area between RNAP and rifampin (386 Å2 and 244 Å2 in WT 
and S531L, respectively).  This dramatically reduces the van der Waals interactions, resulting in a 
large loss of binding free energy and is consistent with drastic increases in IC50 of rifampin for the 
Ser  Leu mutants compared to WT RNAP (Table V-3).  Fork loop 2 is ordered in the S531L RNAP 
without rifampin bound (Figure V-A2), suggesting that the steric clash between rifampin and the 
Leu side chain causes the observed disorder. 
Figure V-7.  Interactions of rifampin with residues of E. coli RNAP (PDB: 5UAC).  Residues in the three most 
clinically relevant mutations as well as Q513 and R540 are shown.   
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Figure V-8.  Structural bases of RifR by clinically relevant mutations S531L, H526Y, and D516V.  Top (A): 
the rifamycin binding pocket of the WT (left) and S531L (right) RNAP complexed with rifampin, shown 
with the β subunit (cyan, transparent molecular surfaces plus cartoon models) and rifampin (sphere 
models).  Middle (B): WT RNAP•RMP (left) and H526Y RNAP with rifampin overlay (right, based on WT 
RNAP•RMP complex).  Arrows indicate locations of steric clash between ansa bridge of rifampin and 
H526Y RNAP.  Bottom (C): Electrostatic surfaces of rifamycin binding pocket of WT (left) and D516V (right) 
RNAP complexed with rifampin (stick models).  RNAP surfaces are colored with positive (blue), negative 
(red) and neutral (white) electrostatic potentials.  Positions of the D516 and V516 residues are indicated 
by red circles. 
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In the WT RNAP•RMP complex, the H526 residue is involved in forming the back wall of 
the rifamycin binding pocket (Figure V-8, B – left) and may form a hydrogen bond with oxygen 
atoms of the ansa bridge and/or the Q513 side chain (Figure V-7).  The crystal structure of H526Y  
RNAP was determined at 3.6 Å resolution.97  A crystal structure with rifampin bound to H526Y 
RNAP was unable to be determined, presumably due to its poor affinity (IC50 ≥ 2000 µM).  
Modeling rifampin from the WT RNAP•RMP complex into the rifamycin binding pocket of H526Y 
RNAP structure shows that the rearranged rifamycin binding pocket would sterically clash with 
the ansa bridge of rifampin (Figure V-8, B – right).  This steric clash is consistent with the high 
level of resistance conferred by the H526Y RNAP in the IC50 values (Table V-3). 
 In the WT RNAP•RMP complex, the D516 residue is involved in forming part of the 
sidewall of the rifamycin binding pocket.  The D516 residue also contribute to rifampin binding 
by van der Waals interactions with the ansa bridge of rifampin and/or charge neutralization of 
basic residues in the rifamycin binding site to facilitate binding of the relatively apolar rifampin.  
There are no major structural changes in the D516V RNAP mutant, with the RNAP•RMP binding 
complex similar to WT RNAP (Figure V-8, C and Figure V-A2).  The main difference between the 
two structures is electrostatic distribution of the rifamycin binding pocket, which becomes more 
basic due to the mutation of AspVal – making it less favorable for rifampin binding. 
Activity of Novel bxRifs on E. coli and MTB RNAPs 
 Concentration-response studies were executed using the plasmid-based transcription 
assay with pMGA4-Ec or pMGA4-Mtb for E. coli and MTB RNAPs, respectively.  A series of novel 
bxRifs and RifB analogs were tested to determine IC50 values against E. coli and MTB RNAPs (WT, 
D516V, and S531L RNAPs – E. coli numbering).  The compounds were clustered into three 
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different groups: Series A – compounds with an n-butyl linker at position R2, Series B – 
compounds with a benzyl linker at position R2, and Series C – compounds with a methyl or formyl 
group at either position R1 or R2. 
Table V-A2 contains IC50 values for a series of RifB analogs against E. coli and MTB RNAPs 
(WT and RifR).  Tables V-A3 thru V-A5 contain IC50 values for novel bxRifs against E. coli and MTB 
RNAPs.  The MICs against replicating (MABA) and non-replicating (LORA) MTB as well as fold 
activation of hPXR are listed in Tables V-A2 thru V-A5.  Rifampin is included at the end of each 
table for reference.  All the compounds tested had similar potency against E. coli and MTB WT 
RNAPs, ranging from < 5 nM to 20 nM.  Most of the compounds were more potent against the 
Asp Val mutant RNAP than the Ser  Leu mutant RNAP.  This was true for both E. coli RNAPs 
and MTB RNAPs.  Most of the compounds were more potent against E. coli than MTB RifR RNAPs.  
This is not surprising since the compounds were designed based on X-ray crystal structures of E. 
coli RNAP with bxRifs. 
When comparing RifB analogs and bxRif compounds with similar R groups, the RifB 
analogs were less potent (257824 vs 262463).  The IC50 values for bxRifs against E. coli RifR RNAPs 
ranged from 0.58 µM to > 1000 µM, while for MTB RifR RNAPs they ranged from 7.2 µM to > 1000 
µM.  The following trends were observed for the bxRif analogs against RifR RNAPs and are 
outlined in Figure V-9. 
1) bxRifs with less flexibility (aromatic ring) in linker at position R2 are more potent 
• 258765 vs 258922 and 262821, 257967 vs 262721, 257983 vs 262806 
2) bxRifs with larger group (isobutyl vs methyl) on piperazine ring at R2 are more potent 
• 262803 vs 262805 
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3) Larger groups on piperazine ring at R1 are tolerated and potentially more potent 
against MTB RNAPs 
• 262823 vs 262824 
4) Carbonyl on piperazine linker at position R2 has minimal effect on potency 
• 257984 vs 257983, 257966 vs 257967 
The novel bxRifs were tested for cellular activity against MTB in culture, and for activation 
of hPXR.  Rifampin has nanomolar cellular potency against MTB (30 and 330 nM –  MABA and 
LORA, respectively).  Rifampin is a strong activator of hPXR, exhibiting a 20 – 30-fold activation 
of hPXR at concentrations of 20 µM or higher in a eukaryotic cell-based hPXR activation assay.  
However, several bxRifs disrupt the eukaryotic cell growth at concentrations that high, which 
affects the reliability of the fold activation in the hPXR assay.  To reliably compare hPXR 
activation, the fold activation at 6.25 µM for each compound is listed in Tables V-A2 thru V-A5, 
where cell viability is > 90% for all compounds tested (determined via MTT assay).  Several 
compounds were identified that had minimal (less than 2) fold-activation at 6.25 µM and were 
more potent against MTB in culture than rifampin (262721, 262725, 262823, 262825).  It was 
Figure V-9.  Overview of bxRif structure-activity relationship studies against RifR RNAP.  Purple:  
Larger substitutions on piperazine are tolerated.  Blue:  Less flexibility in linker is better for activity.  
Green:  Substitution (carbonyl) on piperazine linker is tolerated.  Brown:  Various substitutions are 
tolerated. 
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observed that compounds with a larger substituent at R1 (e.g. piperazine) were less likely to 
activate hPXR.  Of the compounds with fold-activation less than 2, all but 262825 have MIC values 
< 16 nM.  It is therefore of interest to test these compounds at lower concentrations to more 
accurately determine the MICs. 
Discussion 
 E. coli WT and RifR RNAPs have been evaluated in vitro and by X-ray crystallography to 
evaluate their effect on rifamycin binding and resistance.  Studies of bxRifs 2b – 2d inhibitory 
activity on E. coli RNAPs agreed with data previously obtained against MTB, indicating that E. coli 
RNAP is an adequate model for studying the interactions of bxRifs with RNAP and correlating 
them to MTB RNAP.  The crystal structures of E. coli WT RNAP with bxRifs confirm the suspected 
interactions and spatial orientation of the designed bxRifs in the rifamycin binding pocket (Figure 
V-4) that were designed based on models from T. thermophilus RNAP•RMP structure.57  This 
confirmation provided additional merit for the development of novel bxRifs that interact with 
the sigma factor to increase binding affinity. 
 Previous in vitro evaluations of bxRifs utilized a rolling circle transcription assay that uses 
a small (45-nt to 90-nt), single-stranded DNA nanocircle.57  Since this is not the best 
representation of cellular transcription, we utilized the plasmid-based transcription assay with 
malachite green detection.  However, E. coli RifR RNAP in the plasmid-based transcription assay 
using pMGA12 was unaffected by increasing concentrations of rifampin (Figure V-5).  A plasmid 
containing three synthetic terminator repeats (synB)122 with four repeats of the malachite green 
aptamer was used (pMGA4-Ec or pMGA4-Mtb) to detect RNAP activity and inhibition by 
rifamycins.  Transcription from this plasmid was susceptible to inhibition by rifampin (Figure V-
109 
 
5).  Since rifamycins inhibit RNA transcription initiation (and not elongation) we postulated that 
due to the lack of terminator sequences on pMGA12, it is possible for the RNAP to continuously 
transcribe RNA in the elongation phase without dissociating from the DNA during the 1.5-hr time 
course of the reaction.  This would result in rifampin being unable to inhibit RNAP while RNAP is 
in the elongation phase. 
To test this hypothesis, a time course experiment in the presence and absence of heparin 
(binds and inactivates RNAP not bound to DNA)121 was done to compare the rates of RNAP 
inactivation by heparin for each plasmid template (Figure V-6).  It was determined that heparin 
immediately binds and inactivates E. coli RNAP when transcribing from pMGA4-Ec, consistent 
with frequent transcription termination.  However, heparin has minimal effect on RNAP (E. coli 
and MTB) transcription from pMGA12.  Even though MTB RifR RNAP transcription from pMGA12 
was inhibited by rifampin (Figure V-5, right), the heparin experiment indicated that minimal 
transcription termination is occurring from pMGA12.  We believe that there is no observable 
inhibition of E. coli RifR RNAP transcription by rifampin (when using pMGA12) because E. coli 
RNAP has a fast transcription rate, and the processivity of the enzyme overshadows the inhibition 
that could be seen if only a single set of repeats were produced.  Conversely, inhibition of MTB 
RifR RNAP transcription from pMGA12 is observable due to the slower rate of transcription, 
preventing the enzyme from transcribing numerous repeats of plasmid DNA within the time 
course of the reaction.  
 With the plasmid-based transcription assay adapted for evaluation of rifamycin inhibition, 
the effect of E. coli RifR RNAPs on rifampin was evaluated by determination of IC50 values for 
rifampin and crystal structures of E. coli RifR RNAPs with and without rifampin.  As previously 
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reported using rolling circle transcription, H526Y RNAP was the most resistant to rifampin.56  The 
contamination from endogenous E. coli WT RNAP was also evaluated and determined for E. coli 
and MTB RifR RNAPs (Appendix V-1).  The MTB RNAPs were determined to not be contaminated 
with endogenous E. coli WT RNAP.  However, E. coli RifR RNAPs were ~25% contaminated with 
endogenous E. coli WT RNAP (Figure V-A1).  This contamination likely resulted from the Histidine 
tag being coded for on the rpoC gene instead of rpoB, where the resistant mutations are, allowing 
for formation and purification of enzyme with endogenous WT rpoB along with RifR RNAP. 
Previous studies have used WT RNAP•RMP complex structures (T. thermophilus, T. 
aquaticus, more recently E. coli) to model the RNAP structures with RifR mutations using 
molecular dynamics simulations or simple amino acid substitutions to postulate the molecular 
mechanisms of resistance.62,117,123,124  The predictions made by Campbell et al. that the D516V 
mutation confers resistance (based on T. aquaticus RNAP•RMP structure) via the loss of negative 
charge are consistent with the E. coli D516V RNAP structures.  However, previous work on RifR 
resistance mechanisms did not identify the resistance mechanisms of the S531L and H526Y RNAP 
supported by the E. coli RifR RNAP crystal structures.  Based on the crystal structures of S531L 
RNAP with and without rifampin (Figure V-8, A), resistance occurs not only from elimination of a 
hydrogen bonding interaction with the naphthalene ring, but also a decrease in van der Waals 
interactions between the β subunit and the naphthalene ring caused by disordering of fork loop 
2.  The disordering of fork loop 2 of E. coli S531L RNAP was only observed with rifampin bound 
(Figure V-8, A and Figure V-A2), supporting the steric clash between rifampin and the Leu side 
chain since structures of E. coli S531L RNAP without rifampin did not exhibit any gross structural 
changes in the rifamycin binding pocket.  In contrast, E. coli H526Y RNAP had significant changes 
111 
 
in the binding pocket, sterically blocking rifampin binding to RNAP (Figure V-8, B).  The H526Y 
RNAP mutation reshapes the binding site, resulting in insensitivity to rifampin at concentrations 
up to 2000 µM (Table V-3).  Based on the structures of the RifR RNAPs, it is not surprising that 
H526Y RNAP is highly resistant to rifamycins. 
 Novel bxRifs and RifB analogs were evaluated for activity against WT and RifR RNAPs (E. 
coli and MTB).  Overall, the bxRif analogs are more potent than the RifB analogs tested.  This is 
consistent with the higher potency of rifalazil, the bxRif these compounds are based on.  
However, RifB analogs are still of interest because they are much more synthetically accessible 
than bxRifs.  Most of the compounds were more potent against the Asp Val mutant RNAP than 
the Ser  Leu mutant RNAP (for both E. coli and MTB).  Evaluation of the bxRifs’ activities shows 
that compounds with an aromatic linker at position R2 are more potent.  Decreasing the flexibility 
of inhibitors can confine them into an active orientation, so it is not surprising that the aromatic 
linker increases potency relative to a saturated hydrocarbon linker.  Modifications to the linker 
between the piperazine and imidazoline (Series A, Table V-A3) are tolerated.  Additional 
modifications could potentially be made on this linker to decrease flexibility.  Most of the novel 
Rif analogs are more active against E. coli RNAPs than MTB RNAPs.  This is not surprising since 
the design of the compounds was based on crystal structures of the E. coli WT RNAP.  The crystal 
structure of M. tuberculosis RNAP has recently been solved and published.125  Further design and 
structural work of bxRifs in complex with bacterial RNAP should be done using the M. tuberculosis 
RNAP to properly evaluate the potential of novel bxRifs as an anti-TB drug. 
 Four of the novel bxRifs evaluated activated hPXR less than 2-fold (262721, 262725, 
262823, 262825) and were more potent than rifampin against MTB in culture.  This is very 
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promising for identification of a rifamycin that does not have the same issues of drug-drug 
interactions via induction of CYP450s.  Additionally, if a more potent rifamycin with good PK/PD 
properties is identified, this could potentially allow for a shorter treatment duration.  It has been 
shown that higher doses of rifamycins could potentially lead to a shorter duration of therapy; 
however, there have been reports of tolerability issues for higher doses.88,126  Therefore, it is 
reasonable to deduct that a more potent rifamycin analog with similar or better tolerability in 
patients could reduce the treatment duration. 
Conclusions 
 X-ray crystal structures of E. coli WT RNAP with novel bxRifs and E. coli RifR RNAPs with 
and without rifampin have been determined.  These structures show that the designed bxRifs 2b 
– 2d interact with the sigma factor when bound to E. coli RNAP.  The E. coli RifR RNAP structures 
indicate structural explanations for the three most clinically relevant mutations conferring 
rifamycin resistance as follows.  In addition to the expected loss of a hydrogen bonding 
interaction with the naphthalene ring of rifampin, the S531L RNAP mutant results in disordering 
of β fork loop 2 (when rifampin is bound) causing a loss of van der Waals interactions between 
fork loop 2 and rifampin.  The H526Y RNAP mutant results in rearranging of the rifamycin binding 
pocket, and overlay of H526Y RNAP and rifampin bound WT RNAP indicates that H526Y RNAP 
would sterically clash with the ansa bridge of rifampin.  This clash prevents rifampin binding and 
is likely the reason the H526Y RNAP confers such a large degree of resistance on rifampin.  As 
previously predicted based on T. thermophilus structures and modelling, the D516V RNAP mutant 
appears to confer resistance based on the change of electrostatics in the binding pocket resulting 
from the loss of the negatively charged Asp. 
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 A series of novel bxRifs have been evaluated for activity against E. coli and MTB RNAPs 
(WT and RifR), against M. tuberculosis in culture, and for activation of hPXR (leads to CYP450 
induction).  We have shown that further improvements can be made for activity against RNAPs 
in vitro and M. tuberculosis in culture.  However, additional improvements are still necessary 
against MTB RifR RNAPs to have clinical significance against drug-resistant TB.  Further evaluation 
in PK/PD studies is necessary for the bxRifs that have improved activity against M. tuberculosis 
and do not activate hPXR. 
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Appendix V-1 
E. coli WT R*NAP Contamination of RifR RNAPs 
 E. coli and MTB RifR RNAPs were tested in the plasmid-based transcription assay with and 
without 200 nM rifampin to evaluate endogenous E. coli WT RNAP contamination from the 
preparation.  MTB RifR RNAPs were not contaminated with endogenous E. coli WT RNAP.  The 
total active RNAP was determined using a radiometric single turnover assay (Max Stefan).  The 
specific activity of WT RNAP was determined by dividing the fluorescence reading by the active 
RNAP concentration.  The amount of contaminating endogenous WT RNAP was determined for 
each RifR mutant, then subtracted from total active RNAP.  The percent RifR mutant in each prep 
determined from the calculations (Table V-A1) are shown in Figure V-A1. 
Table V-A1.  Determination of endogenous E. coli WT RNAP in RifR mutant purifications 
E. coli RNAPs WT D516V H526Y S531L 
Active RNAP (%) 100 ± 4 104 ± 3 75 ± 3 64 ± 1 
[Total RNAP]Active (nM) 20 20.8 15 12.8 
Fluorescence, - RMP (RFU) 14823 8460 4215.5 7089 
Specific Activity (RFU/nM) 741    
Fluorescence, WT contaminant (RFU) N/A 3557 2890 1704 
[WT RNAP]contaminant (nM) N/A 4.8 3.9 2.3 
Percent RifR RNAP N/A 77% 74% 82% 
  
Figure V-A1.  Percent RifR mutant in E. coli and MTB RNAP Purifications.  Left:  Percent RifR mutants for E. 
coli RNAPs.  Right:  Percent RifR mutants for MTB RNAPs. 
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Appendix V-2 
X-Ray Crystal Structures of E. coli RNAPs 
Crystallization studies were performed by Drs. Vadim Molodtsov and Katsu Murakami as 
described.97 
Figure V-A2.  Electron density maps of RNAP and RNAP•RMP complexes.  2FO – FC electron density map 
(gray mesh, σ cutoff = 1) of WT RNAP•RMP complex (A), S531L RNAP (B), S531L RNAP•RMP complex (C) 
and D516V RNAP•RMP complex (D). The subunit and rifampin are shown as cartoon and stick models, 
respectively.  Fork loop 2 of β subunit is colored in blue and labeled. The disordered fork loop 2 in the 
S531L RNAP•RMP complex is indicated as a dashed line. 
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Appendix V-3 
IC50 Values of bxRifs and RifB Analogs 
 IC50 values were determined against E. coli and MTB RNAPs using the plasmid-based 
transcription assay.  WT enzymes were tested at 5 nM RNAP, 15 nM σ70/SigA, and 10 nM pMGA4-
Ec or pMGA4-Mtb.  RifR RNAPs were tested ad 40 nM RNAP, 120 nM σ70/SigA, and 80 nM pMGA4-
Ec or 40 nM pMGA4-Mtb.  Compounds were tested at concentrations of 0.78 – 400 nM for WT 
RNAPs and 0.24 – 1000 µM for RifR RNAPs. 
 
Table V-A2.  In vitro activity of RifB analogs against E. coli and MTB RNAPs 
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Table V-A3.  In vitro activity of benzoxazinorifamycins Series A against E. coli and MTB RNAPs 
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Table V-A4.  In vitro activity of benzoxazinorifamycins Series B against E. coli and MTB RNAPs 
 
 
Table V-A5.  In vitro activity of benzoxazinorifamycins Series C against E. coli and MTB RNAPs  
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Chapter VI 
Summary, Conclusions, and Future Directions 
 Tuberculosis (TB) is an infectious disease caused by the pathogen Mycobacterium 
tuberculosis, and is one of the largest global health problems, infecting an estimated 8 – 10 
million new people each year.2  The issue of drug-resistant TB has resulted in a growing global 
concern due to the prevalence of resistant strains and the limited number of novel anti-TB drugs 
in development.127,128  Reinvestigation of bacterial RNA polymerase for drug-resistant TB is of 
interest since introduction of rifampin in the 1960s led to a reduction in therapy from 18 months 
to 9 months, with a current treatment regimen of 6 months with rifampin and three other 
drugs.43  This dissertation focused on studying novel inhibitors of bacterial RNA polymerase 
(RNAP) for their potential as inhibitors of M. tuberculosis wild-type (WT) and rifampin-resistant 
(RifR) RNAP.   
 In chapter II, a plasmid-based transcription assay was developed and optimized using an 
RNA aptamer that binds malachite green, resulting in an increase in fluorescence of malachite 
green.  This assay utilizes a plasmid template, is cost effective, and is amenable to high-
throughput screening.  It was shown to be able to detect concentration-dependent inhibition of 
E. coli RNAP by rifampin. 
 In chapter III, the plasmid-based transcription assay was optimized and implemented for 
a high-throughput screen against the E. coli RNAP analog (βS531L/β’V408G) of the most clinically 
relevant M. tuberculosis rifampin-resistant (RifR) RNAP.  This RNAP contains a mutation that 
121 
 
confers rifamycin resistance (βS531L) as well as a compensatory mutation (β’V408G) that is 
believed to ameliorate a fitness defect.89  The high-throughput screen resulted in identification 
of 15 compounds with IC50 values against E. coli or MTB RNAP less than 100 µM. 
 In chapter IV, the top scaffolds identified from the high-throughput screen were 
evaluated for their activity against bacterial RNAP, M. tuberculosis in culture, and their potential 
for further development against bacterial RNAP.  Several scaffolds of interest were evaluated by 
an initial structure-activity relationship study with commercially available analogs.  A 
cyanopyrimidine scaffold was identified as a specific inhibitor of bacterial RNAP with the 
potential to be further optimized.  It inhibited both WT and RifR RNAP (E. coli and MTB), and was 
evaluated for potential pan-assay interference that could be caused by an aromatic nitrile.  The 
scaffold was found to reversibly inhibit RNAP and does not form an adduct with cysteine in a 
nitrile reactivity assay, which has previously been used to evaluate the electrophilicity of 
aromatic nitriles.100 
 In chapter V, we determined structures of E. coli WT RNAP with bxRifs that confirmed 
interactions between bxRifs and the sigma factor, providing further merit to pursue optimization 
of bxRifs for improved binding and potency.  We evaluated the effects of RifR mutations on RNAP 
as well as their effects on rifampin binding and inhibition of RNAP.  Structures of E. coli RifR RNAPs 
with and without rifampin identified resistance mechanisms beyond previous modeling and 
predictions made from wild-type bacterial RNAPs (T. thermophilus, T. aquaticus, E. coli).  In 
addition, we developed and evaluated novel bxRifs designed based on crystal structures of E. coli 
RNAP in complex with bxRifs.  We identified novel bxRifs that are more potent against M. 
tuberculosis in culture than rifampin and show minimal activation of hPXR. 
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In conclusion, we have identified novel compounds (cyanopyrimidines) that are able to 
inhibit both WT and RifR RNAP (E. coli and MTB).  These compounds have modest activity in vitro 
(low µM at best) and further structure-activity studies are necessary to identify more potent 
analogs.  Identification of the binding site of this scaffold would allow for structure-based design 
of cyanopyrimidines with improved activity.  X-ray crystal structures of RNAP in complex with an 
active cyanopyrimidine, followed by mutagenesis studies to confirm binding site would aid in the 
development of this scaffold as a potent RNAP inhibitor. 
We have also developed novel bxRifs with modest improvements in activity against RifR 
RNAPs.  Further, several bxRifs developed are exceedingly potent against M. tuberculosis in 
culture (< 16 nM) and show minimal activation of the human pregnane X receptor, which leads 
to CYP450 induction and drug-drug interactions in patients.  These compounds warrant further 
work to evaluate their pharmacokinetic and pharmacodynamic properties, followed by studies 
in mice. 
To further aid in the fight against TB and drug-resistance, as well as working towards the 
eradication of TB, significant progress is still needed.  The current 6-month treatment for drug-
sensitive TB still presents difficulties in adherence throughout the entire regimen.  Research has 
indicated that higher concentrations of rifampin, if tolerated, could reduce the treatment 
regimen.126  If modifications to the current treatment regimen resulted in a shorter duration of 
treatment, this could help decrease the burden of drug administration and adherence.  The long 
treatment duration results in difficulties not only in adherence, but also administration. 
Since 1994, The World Health Organization has recommended a direct observed therapy, 
short-course (DOTS) for the treatment and eradication of TB; where hospital workers or trained 
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volunteers directly observe and record the swallowing of pills.129  This strategy outlined a 
framework for effective identification and treatment of TB.  This framework has been expanded 
upon to include MDR-TB treatment; however, there are still issues with effective administration 
and treatment in countries with impoverished health systems.129  In countries where some of the 
main tenants of DOTS (government commitment, steady drug supply, standardized recording and 
reporting) are compromised, it is important to alleviate and simplify these issues.  The high cost 
of second-line TB drugs for MDR-TB and the inability to directly observe and record treatment 
are both hurdles in remote areas with impoverished health systems.  The implementation of a 
treatment administration strategy that that allows for the successful completion of TB treatment, 
even in remote areas, will help aid in the fight to eradicate TB. 
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